A Phase 2 interventional study of CAB Oral Tablets and CAB LA in Infection, Human Immunodeficiency Virus and HIV Infections, sponsored by ViiV Healthcare. Completed at 50 sites in 5 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2024-06-12.
Sponsored by ViiV Healthcare (part of GlaxoSmithKline) · Phase 2, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 36 studies testing cabotegravir in HIV Infections — 4 open to participants now, 13 under way, 8 of them phase 3. cabotegravir · HIV Infections.
Among the 36 studies testing cabotegravir in HIV Infections, this one is the 13th largest by enrollment, is the only one that started in 2014, is one of 8 in phase 2, and was the 5th registered.
4,737 studies on the registry are indexed under HIV Infections; 246 are open to participants now.
Browse HIV Infections studies →4 of the 36 studies testing cabotegravir in HIV Infections are open now, in 3 countries. Recruiting first, the newest first:
ViiV Healthcare · Sites in South Africa
Ages up to 10 days · Healthy volunteers
Africa Health Research Institute · Sites in South Africa
Ages 15–30 · Healthy volunteers
Evandro Chagas National Institute of Infectious Disease · Sites in Brazil
Ages 18–30 · Men only · Healthy volunteers
Duke University · Sites in United States
Ages 18+ · Healthy volunteers
By country, each count listing its studies:
cabotegravir: first FDA approval 2021 (VOCABRIA), first EMA approval 2020. What it is approved for, and how studies give it, is on its page →
Of the 159 HIV Infections studies recruiting now, 104 (65%) set no upper age limit and 42 (26%) stop at 75 or younger; 31 take children under 18; 60 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
36 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 12 · Phase 2 11 · Phase 3 13 · Phase 4 3
First in 2008; this study’s year is marked. 1 started in 2014.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 309 is above the median of 80 across 3,491 interventional studies indexed under HIV Infections.
Median enrollment 200 across the 36 interventional studies. Of the 23 that completed or were terminated, 18 (78%) have results posted.
This tab as a report to print or save as PDF → With an account.
25 of 36 have an industry lead sponsor. The 7 most frequent:
This study is registered under ViiV Healthcare, one of the names counted as GlaxoSmithKline. Under that name alone:
ViiV Healthcare is the lead sponsor of 267 studies on the registry; 18 are open to participants now.
Of its 71 completed or terminated interventional studies of FDA-regulated products, 53 (75%) have results posted.
266 studies in HIV Infections by GlaxoSmithKline: 15 open now, 27 under way, 8 of them phase 3. Of 230 finished, 95 (41%) have results posted.
Among the 266 studies in HIV Infections by GlaxoSmithKline, this one is the 42nd largest by enrollment of the 210 interventional ones that give a count, is one of 5 that started in 2014, is one of 48 in phase 2, and was the 153rd registered.
GlaxoSmithKline’s HIV Infections studies by the year they started, since 1994.
1 of the studies testing cabotegravir in HIV Infections that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT06786520ViiV HealthcareA Study to Evaluate the Pharmacokinetics, Safety, and Tolerability of Cabotegravir Ultra Long-acting (CAB ULA) Following Switch From Cabotegravir Long-acting (CAB LA) in Healthy Adults | 2027-03-08 |
Add it to your calendar (.ics) → With an account.
Among the 36 studies testing cabotegravir in HIV Infections, from their registry updates:
Among GlaxoSmithKline’s 266 in HIV Infections:
This tab as a report to print or save as PDF → With an account.
This study is a Phase IIb, randomized, multicentre, parallel group, open-label, study having an overall objective to evaluate the antiviral activity, tolerability, and safety of two intramuscular (IM) dosing regimens of GSK744 LA plus TMC278 LA, relative to GSK744 30 milligram (mg) plus Abacavir/Lamivudine (ABC/3TC) given orally once daily (QD), in HIV-1 infected antiretroviral-naïve subjects. GSK744 is the oral formulation of GSK1265744 (cabotegravir), GSK744 LA is the long acting injectable formulation of GSK1265744 and TMC278 LA is the long acting injectable formulation of TMC278.
The study will consist of three parts: an Induction Period, Maintenance Period and Extension Period. There is also a Long-Term Follow Up Period for subjects who withdraw from the study and have received at least one dose of GSK744 LA and / or TMC278 LA. In the Induction Period, eligible subjects will receive a combination of an oral regimen of 30 mg of GSK744 and 600/300 mg of ABC/3TC, once daily for 20 weeks. In the Maintenance Period, eligible subjects will be randomized 2:2:1 at Day 1 to receive an IM regimen of GSK744 LA 400 mg + TMC278 LA 600 mg every 4 weeks for 96 weeks (Q4W), an IM regimen of GSK744 LA 600 mg + TMC278 LA 900 mg every 8 weeks for 96 weeks (Q8W), or to continue on the oral Induction Period regimen of GSK744 30 mg + ABC/3TC once daily for 96 weeks (or 104 weeks if continuing on to the Extension Period). The Extension Period will allow for a collection of longer term efficacy and safety and tolerability data from subjects receiving GSK744 LA and TMC278 LA.
The study will involve sufficient subjects at screening in order to ensure a total of approximately 265 subjects at the beginning of the Induction Period and approximately 225 subjects randomized into the Maintenance Period.
4,737 studies on the registry are indexed under HIV Infections; 246 are open to participants now.
This study's enrollment of 309 is above the median of 80 across 3,491 interventional studies indexed under HIV Infections.
Browse HIV Infections studies →ViiV Healthcare is the lead sponsor of 267 studies on the registry; 18 are open to participants now.
Of its 71 completed or terminated interventional studies of FDA-regulated products, 53 (75%) have results posted.
Compared within HIV Infections, this study's primary condition as ClinicalTrials.gg classifies it; the registry's first condition term is Infections. The counts are of registry records indexed under each term, refreshed daily. How we classify →
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
The number of CD4 cells, a type of white blood cell, in a given amount of blood. It is used to follow how well the immune system is doing in HIV.
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.
Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.
Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.
After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.
On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.
The study may name a correction formula and a limit in milliseconds, often around 450–480.
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
How quickly the kidneys clear creatinine, a waste product, from the blood. A study may estimate it from a blood test with age, weight and sex (often by the Cockcroft–Gault formula), or measure it using blood and urine collected over a set time. Given in mL/min; higher is better.
Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.
Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.
The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.
“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.
A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.
Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.
A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
HIV
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Childbearing potential
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Postmenopausal
Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraception
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
CD4 count
The number of CD4 cells, a type of white blood cell, in a given amount of blood. It is used to follow how well the immune system is doing in HIV.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Clinically significant
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hepatitis B tests
Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.
Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hepatitis C tests
Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.
After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
QT and QTc
On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.
The study may name a correction formula and a limit in milliseconds, often around 450–480.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Investigational drug or device
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Creatinine clearance (CrCl)
How quickly the kidneys clear creatinine, a waste product, from the blood. A study may estimate it from a blood test with age, weight and sex (often by the Cockcroft–Gault formula), or measure it using blood and urine collected over a set time. Given in mL/min; higher is better.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ALT and AST (liver enzymes)
Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.
Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ULN (upper limit of normal)
The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.
“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Bilirubin
A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.
Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ECG (electrocardiogram)
A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Corticosteroids (steroids)
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
On Day 1 of the Maintenance period, participants who successfully completed the Induction period, were randomized to receive following intramuscular (IM) doses: Day 1 only: CAB long acting (LA) 800 mg (loading dose delivered as two 400 mg IM injections) + RPV LA 900 mg IM; Week 4 only: CAB LA 600 mg IM (second loading dose, no RPV); and from Week 8: CAB LA 600 mg IM +RPV LA 900 mg IM every 8 Weeks (Q8W) for 96 weeks. Eligible participants had the option to continue study participation in the Extension Period.
Drug: CAB LA · Drug: RPV
On Day 1 of the Maintenance period, participants who successfully completed the Induction period, were randomized to receive following IM doses: Day 1 only: CAB LA 800 mg (loading dose delivered as two 400 mg IM injections) + RPV LA 600 mg IM; and from Week 4: CAB LA 400 mg IM + RPV LA 600 mg IM every 4 Weeks (Q4W) for 96 weeks. Eligible participants had the option to continue study participation in the Extension Period.
Drug: CAB LA · Drug: RPV
In induction period, all participants received an oral regimen of cabotegravir (CAB) 30 milligrams (mg) once daily (QD) plus abacavir/lamivudine (ABC/3TC) 600/300 mg QD for 20 weeks. They also received an oral dose of Rilpivirine (RPV) 25 mg tablet once daily in the last 4 weeks of the Induction Period.
Drug: CAB Oral Tablets · Drug: ABC/3TC Oral tablets · Drug: RPV Oral Tablets
On Day 1 of the Maintenance period, participants who successfully completed the Induction period, were randomized to receive CAB and ABC/3TC QD for 96 weeks. Eligible participants had the option to continue study participation in Extension Period by switching to an optimized IM CAB LA+ RPV LA regimen of their choice (Q8W or Q4W).
Drug: CAB Oral Tablets · Drug: ABC/3TC Oral tablets · Drug: RPV Oral Tablets
Participants who completed 96 weeks of CAB 30 mg + ABC/3TC QD regimen in Maintenance Period transitioned to Extension Period and received an optimized loading dose of CAB LA 600 mg+RPV LA 900 mg IM at Week 100 and Week 104 followed by CAB LA 600 mg+RPV LA 900 mg IM-Q8W in the Extension Phase. Participants were followed up until end of Extension Period.
Drug: CAB LA · Drug: RPV
Participants who completed 96 weeks of CAB 30 mg + ABC/3TC QD regimen in Maintenance Period transitioned to Extension Period and received an optimized loading dose of CAB LA 400 mg+RPV LA 900 mg IM at Week 100 followed by CAB LA 400 mg+RPV LA 900 mg IM-Q8W in the Extension Phase. Participants were followed up until end of Extension Period.
Drug: CAB LA · Drug: RPV
This group included participants that were withdrawn from CAB LA+RPV LA IM regimens based on protocol criteria and were required to access Highly Active Antiretroviral Therapy (HAART) of choice. Participants were followed up for approximately 52 weeks.
Other: HAART
White to almost white oval shaped film coated 30 mg tablets for oral administration.
Sterile white to slightly colored suspension containing 200 mg/mL of GSK744 as free acid (GSK1265744 free acid), polysorbate 20, polyethylene glycol 3350, mannitol, and water for injection, packaged in a 3 mL USP Type I glass vial, for administration by IM injection
ABC/3TC fixed dose combination (FDC) oral tablet, containing 600 mg of ABC (as abacavir sulfate) and 300 mg of 3TC
Off-white, round, biconvex, film-coated 25 mg Rilpivirine (RPV) tablets for oral administration. Eligible subjects switching from the oral regimen to the IM regimen in the Extension Period will receive 2 weeks of RPV 25 mg once daily, from Week 102 through Week 104
Higly-active antiretroviral therapy chosen by participant based on investigator recommendations and based on availability.
Sterile white suspension containing 300 mg/mL of TMC278 as free base, poloxamer 338, sodium dihydrogen phosphate monohydrate, citric acid monohydrate, glucose monohydrate, sodium hydroxide, water for injection, packaged in a 2 mL USP Type I glass vial, for administration by IM injection.
Percentage of Participants With Plasma Human Immunodeficiency Virus-1 (HIV-1) Ribonucleic Acid (RNA) Level Below 50 Copies/Milliliter (c/mL) at Week 32
Percentage of participants with HIV-1 RNA\<50 c/mL was obtained using Food and Drug Administration (FDA) Snapshot algorithm. The algorithm treated all participants without HIV-1 RNA data at the visit of interest (due to missing data or discontinuation of investigational product prior to the visit window) as well as participants who switch their concomitant antiretroviral therapy (ART) prior to the visit of interest as non-responders. The Intent-to-Treat Maintenance Exposed (ITT-ME) Population consisted of all randomized participants who received at least one injection or one dose of investigational product during the Maintenance Period of the study (on or after Day 1 visit).
Time frame: Week 32
Number of Participants With Protocol Defined Virologic Failure (PDVF) Until Week 32
Virologic failure was defined as any of the following: (1) Non-response as indicated by a less than 1.0 logarithm to base 10 (log10) c/mL decrease in plasma HIV-1 RNA after 4 weeks of starting the Induction Period, which is subsequently confirmed, unless the plasma HIV-1 RNA is \< 400 c/mL; (2) Rebound as indicated by two consecutive plasma HIV-1 RNA levels \>=200 c/mL after prior suppression to \< 200 c/mL; (3) Rebound as indicated by two consecutive plasma HIV-1 RNA that are \> 0.5 log10 c/mL increase in plasma HIV-1 RNA from the nadir value on study, where the lowest HIV-1 RNA value is \>=200 c/mL.
Time frame: Up to Week 32
Number of Participants With Any Serious Adverse Event (SAE) and Any Non-serious Adverse Event (Non-SAE) (Induction Period)
An AE is defined as any untoward medical occurrence in a participant or clinical investigation participant, temporally associated with the use of a medicinal product, whether or not considered related to the medicinal product. A SAE is defined as any untoward medical occurrence that, at any dose, results in death, is life threatening, requires hospitalization or prolongation of existing hospitalization, results in disability/incapacity, or is a congenital anomaly/birth defect, important medical events which may require medical or surgical intervention, drug-induced liver injury with hyperbilirubinaemia.
Time frame: Up to 20 weeks
Number of Participants With Any Serious Adverse Event (SAE) and Any Non-serious Adverse Event (Non-SAE) (Maintenance Period)
An AE is defined as any untoward medical occurrence in a participant or clinical investigation participant, temporally associated with the use of a medicinal product, whether or not considered related to the medicinal product. A SAE is defined as any untoward medical occurrence that, at any dose, results in death, is life threatening, requires hospitalization or prolongation of existing hospitalization, results in disability/incapacity, or is a congenital anomaly/birth defect, important medical events which may require medical or surgical intervention, drug-induced liver injury with hyperbilirubinaemia. Data presented includes all post-baseline induction period and maintenance period adverse events, as well as long-term follow-up period adverse events for those participants who did not enter the extension period.
Time frame: Up to an average of 59 weeks
Number of Participants With Post-Baseline Adverse Events by Maximum Toxicity Grade
An AE is defined as any untoward medical occurrence in a participant or clinical investigation participant, temporally associated with the use of a medicinal product, whether or not considered related to the medicinal product. Toxicity was graded according to Division of Acquired Immunodeficiency Syndrome (DAIDS) grading criteria, where Grade 1-mild, Grade 2-moderate, Grade 3-severe, Grade 4-potentially life-threatening. Data presented includes all post-baseline treatment emergent Induction Period and MP toxicities, as well as LTFP toxicities for those participants who did not enter the extension period. Number of participants with post-Baseline adverse events by maximum toxicity Grade have been presented.
Time frame: Up to an average of 59 weeks
Number of Participants With Maximum Post-Baseline Emergent Toxicities for Clinical Chemistry Parameters
Clinical chemistry parameters aspartate amino transferase (AST), alanine amino transferase (ALT), alkaline phosphatase (ALP), carbon dioxide(CO2) content/bicarbonate (HCO3), cholesterol, creatine kinase (CK), glucose, low density lipoprotein (LDL) cholesterol, lipase, potassium, and sodium, total bilirubin (TBIL) and triglycerides were evaluated. Toxicity was graded according to Division of Acquired Immunodeficiency Syndrome (DAIDS) grading criteria, where Grade 1-mild, Grade 2-moderate, Grade 3-severe, Grade 4-potentially life-threatening. Data presented includes all post-baseline treatment emergent Induction Period and MP toxicities, as well as LTFP toxicities for those participants who did not enter the extension period. Number of participants with any time post-baseline maximum emergent toxicities in any of the chemistry parameters have been presented.
Time frame: Up to an average of 59 weeks
Number of Participants With Maximum Post-Baseline Emergent Toxicities for Hematology Parameters
Hematology parameters hemoglobin, platelet count, total neutrophils and white blood cell count were evaluated. Toxicity was graded according to DAIDS grading criteria, where Grade 1-mild, Grade 2-moderate, Grade 3-severe, Grade 4-potentially life-threatening. Data presented includes all post-baseline treatment emergent Induction Period and MP toxicities, as well as LTFP toxicities for those participants who did not enter the extension period. Number of participants with any time post-baseline maximum emergent toxicities in any of the hematology parameters have been presented.
Time frame: Up to an average of 59 weeks
Number of Participants With Post-Baseline Urinalysis Dipstick Results
Urinalysis dipstick included urine occult blood, urine glucose, urine ketones, urine nitrite, urine protein and urine leukocyte. The dipstick test gives results in a semi-quantitative manner and results for urinalysis parameters can be read as positive, trace, 1+, 2+ and 3+ indicating proportional concentrations in the urine sample. Data presented includes all post-baseline dipstick results during Induction and Maintenance Periods, as well as LTFP for those participants who did not enter the extension period.
Time frame: Up to an average of 59 weeks
Percentage of Participants With Plasma HIV-1 RNA <200 c/mL and <50 c/mL, for Oral Dose of CAB 30 mg Plus ABC/3TC (Induction Period)
Percentage of participants with HIV-1 RNA \<200 c/mL and \<50 c/mL for oral dose of CAB 30 mg plus ABC/3TC during Induction Period was obtained using FDA Snapshot algorithm. The algorithm treated all participants without HIV-1 RNA data at the visit of interest (due to missing data or discontinuation of investigational product prior to the visit window) as well as participants who switch their concomitant ART prior to the visit of interest, as non-responders. The Intent-to-Treat Exposed (ITT-E) Population consisted of all randomized participants who received at least one dose of investigational product.
Time frame: Week -20, Week -16, Week -12, Week -8, Week -4, Day 1
Absolute Values of Plasma HIV-1 RNA, for Oral Dose of CAB 30 mg Plus ABC/3TC (Induction Period)
Plasma samples for quantitative HIV-1 RNA were collected at indicated time points. Log10 values for HIV-1 RNA have been presented.
Time frame: Week -20, Week -16, Week -12, Week -8, Week -4, Day 1
Change From Baseline in Plasma HIV-1 RNA, for Oral Dose of CAB 30 mg Plus ABC/3TC (Induction Period)
Plasma samples for quantitative HIV-1 RNA were collected at indicated time points. Baseline (Week -20) refers to the last available value up to and including the date of first induction period dosing with CAB 30 mg plus ABC/3TC. Change from Baseline was defined as: HIV-1 RNA(log 10) at post-baseline visit minus HIV-1 RNA(log 10) at Baseline.
Time frame: Baseline (Week -20) and Week -16, Week -12, Week -8, Week -4, Day 1
Absolute Values of Cluster of Differentiation 4+ (CD4+), for Oral Dose of CAB 30 mg Plus ABC/3TC (Induction Period)
Blood samples were collected at specified time points to assess CD4+ using flow cytometry. Mean and standard deviation values for CD4+ are presented.
Time frame: Week -20, Week -16, Week -12, Week -4, Day 1
Change From Baseline in CD4+, for Oral Dose of CAB 30 mg Plus ABC/3TC (Induction Period)
Blood samples were collected at specified time points to assess CD4+. It was evaluated by flow cytometry. Baseline (Week -20) refers to the last available value up to and including the date of first induction period dosing with CAB 30 mg plus ABC/3TC. Change from Baseline was defined as value at post-baseline visit minus value at Baseline.
Time frame: Baseline (Week -20) and Week -16, Week -12, Week -4, Day 1
Number of Participants With AEs by Their Severity Grades, for Oral Dose of CAB 30 mg Plus ABC/3TC (Induction Period)
An AE is any untoward medical occurrence in a clinical investigation participant, temporally associated with the use of a medicinal product, whether or not considered related to the medicinal product. Adverse events were evaluated by the investigator and graded according to the DAIDS toxicity grading, where Grade 1=Mild, 2=Moderate, 3=Severe, 4=Potentially life threatening. The higher the grade, the more severe the symptoms. Number of participants with adverse events by maximum grade have been presented.
Time frame: Up to 20 Weeks
Number of Participants With Maximum Post-Baseline Emergent Toxicities for Hematology Parameters, for Oral Dose of CAB 30 mg Plus ABC/3TC (Induction Period)
Hematology parameters hemoglobin, platelet count, total neutrophils and white blood cell count were evaluated. Laboratory toxicities were graded according to DAIDS grading criteria, where Grade 1-mild, Grade 2-moderate, Grade 3-severe, Grade 4-potentially life-threatening. Number of participants with any time post-baseline maximum emergent toxicities in any of the hematology parameters have been presented.
Time frame: Up to Week 20
Number of Participants With Maximum Post-Baseline Emergent Toxicities for Clinical Chemistry Parameters, for Oral Dose of CAB 30 mg Plus ABC/3TC (Induction Period)
Clinical chemistry parameters AST, ALT, ALP, CO2/HCO3, cholesterol, CK, glucose, LDL cholesterol, lipase, potassium, and sodium, total TBIL and triglycerides were evaluated. Laboratory toxicities were graded according to DAIDS grading criteria, where Grade 1-mild, Grade 2-moderate, Grade 3-severe, Grade 4-potentially life-threatening. Number of participants with any time post-baseline maximum emergent toxicities in any of the chemistry parameters have been presented.
Time frame: Up to 20 weeks
Change From Baseline in Clinical Chemistry Parameters: ALT, ALP, AST and CK (Induction Period)
Blood samples were collected for the analysis of clinical chemistry parameters including ALT, ALP, AST and CK at indicated time points. Baseline (Week -20) refers to the last available value up to and including the date of first induction period dosing with CAB 30 mg plus ABC/3TC. Change from Baseline was defined as value at post-baseline visit minus value at Baseline.
Time frame: Baseline (Week -20) and Week -16, Week -12, Week -8, Week -4, Day 1
Change From Baseline in Clinical Chemistry Parameter: Albumin (Induction Period)
Blood samples were collected for the analysis of clinical chemistry parameter: Albumin at indicated time points. Baseline (Week -20) refers to the last available value up to and including the date of first induction period dosing with CAB 30 mg plus ABC/3TC. Change from Baseline was defined as value at post-baseline visit minus value at Baseline.
Time frame: Baseline (Week -20) and Week -16, Week -12, Week -8, Week -4, Day 1
Change From Baseline in Clinical Chemistry Parameters: Total Bilirubin and Creatinine (Induction Period)
Blood samples were collected for the analysis of clinical chemistry parameters including total Bilirubin and Creatinine at indicated time points. Baseline (Week -20) refers to the last available value up to and including the date of first induction period dosing with CAB 30 mg plus ABC/3TC. Change from Baseline was defined as value at post-baseline visit minus value at Baseline.
Time frame: Baseline (Week -20) and Week -16, Week -12, Week -8, Week -4, Day 1
Change From Baseline in Clinical Chemistry Parameters: CO2, Chloride, Cholesterol, Glucose, Potassium, Sodium, Triglyceride and Urea (Induction Period)
Blood samples were collected for the analysis of clinical chemistry parameters including total CO2, chloride, cholesterol, glucose, potassium, sodium, triglyceride and urea at indicated time points. Baseline (Week -20) refers to the last available value up to and including the date of first induction period dosing with CAB 30 mg plus ABC/3TC. Change from Baseline was defined as value at post-baseline visit minus value at Baseline.
Time frame: Baseline (Week -20) and Week -16, Week -12, Week -8, Week -4, Day 1
Change From Baseline in Clinical Chemistry Parameter: Lipase (Induction Period)
Blood samples were collected for the analysis of clinical chemistry parameter: Lipase at indicated time points. Baseline (Week -20) refers to the last available value up to and including the date of first induction period dosing with CAB 30 mg plus ABC/3TC. Change from Baseline was defined as value at post-baseline visit minus value at Baseline.
Time frame: Baseline (Week -20) and Week -16, Week -12, Week -8, Week -4, Day 1
Change From Baseline in Hematology Parameters: Basophil, Eosinophils, Lymphocytes, Total Neutrophils, Monocytes, Platelets Count and White Blood Cells (WBC) Count (Induction Period)
Blood samples were collected for the analysis of hematology parameters: Basophil, Eosinophils, Lymphocytes, Total Neutrophils, Monocytes, Platelets count and WBC at indicated time points. Baseline (Week -20) refers to the last available value up to and including the date of first induction period dosing with CAB 30 mg plus ABC/3TC. Change from Baseline was defined as value at post-baseline visit minus value at Baseline.
Time frame: Baseline (Week -20) and Week -16, Week -12, Week -8, Week -4, Day 1
Change From Baseline in Hematology Parameter: Hematocrit (Induction Period)
Blood samples were collected for the analysis of hematology parameter: Hematocrit at indicated time points. Baseline (Week -20) refers to the last available value up to and including the date of first induction period dosing with CAB 30 mg plus ABC/3TC. Change from Baseline was defined as value at post-baseline visit minus value at Baseline.
Time frame: Baseline (Week -20) and Week -16, Week -12, Week -8, Week -4, Day 1
Change From Baseline in Hematology Parameter: Hemoglobin (Induction Period)
Blood samples were collected for the analysis of hematology parameter: Hemoglobin at indicated time points. Baseline (Week -20) refers to the last available value up to and including the date of first induction period dosing with CAB 30 mg plus ABC/3TC. Change from Baseline was defined as value at post-baseline visit minus value at Baseline.
Time frame: Baseline (Week -20) and Week -16, Week -12, Week -8, Week -4, Day 1
Change From Baseline in Hematology Parameter: Mean Corpuscle Volume (Induction Period)
Blood samples were collected for the analysis of hematology parameter: Mean Corpuscle Volume at indicated time points. Baseline (Week -20) refers to the last available value up to and including the date of first induction period dosing with CAB 30 mg plus ABC/3TC. Change from Baseline was defined as value at post-baseline visit minus value at Baseline.
Time frame: Baseline (Week -20) and Week -16, Week -12, Week -8, Week -4, Day 1
Change From Baseline in Hematology Parameter: Red Blood Cell Count (Induction Period)
Blood samples were collected for the analysis of hematology parameter: Red Blood Cell count at indicated time points. Baseline (Week -20) refers to the last available value up to and including the date of first induction period dosing with CAB 30 mg plus ABC/3TC. Change from Baseline was defined as value at post-baseline visit minus value at Baseline.
Time frame: Baseline (Week -20) and Week -16, Week -12, Week -8, Week -4, Day 1
Percentage of Participants With Plasma HIV-1 RNA Level <50 c/mL and <200 c/mL Over Week 96 (Maintenance Period)
Percentage of participants with HIV-1 RNA \<50 c/mL and \<200 c/mL was obtained using FDA Snapshot algorithm. The algorithm treated all participants without HIV-1 RNA data at the visit of interest (due to missing data or discontinuation of investigational product prior to the visit window) as well as participants who switch their concomitant ART prior to the visit of interest, as non-responders.
Time frame: From Day 1 up to Week 96
Number of Participants With Protocol Defined Virologic Failure at Week 32 and Week 48 (Maintenance Period)
Virologic failure was defined as any of the following: (1) Non-response as indicated by a less than a 1.0 log10 c/mL decrease in plasma HIV-1 RNA after 4 weeks of starting the Induction Period, which is subsequently confirmed, unless the plasma HIV-1 RNA is \< 400 c/mL; (2) Rebound as indicated by two consecutive plasma HIV-1 RNA levels \>=200 c/mL after prior suppression to \< 200 c/mL; (3) Rebound as indicated by two consecutive plasma HIV-1 RNA that are \> 0.5 log10 c/mL increase in plasma HIV-1 RNA from the nadir value on study, where the lowest HIV-1 RNA value is \>=200 c/mL.
Time frame: At Week 32 and Week 48
Absolute Value of Plasma HIV-1 RNA at Week 32 and Week 96 (Maintenance Period)
Plasma samples for quantitative HIV-1 RNA analysis were collected at indicated time points during Maintenance Period. Log10 values for HIV-1 RNA have been presented. SD=0.000 is defined as following: if participants analyzed at a specific timepoint have resulted same values, then SD is considered equal with 0.000.
Time frame: At Week 32 and Week 96
Change From Baseline in Plasma HIV-1 RNA at Week 32 and Week 96 (Maintenance Period)
Plasma samples for quantitative HIV-1 RNA analysis were collected at indicated time points during Maintenance Period. Baseline (Week -20) refers to the last available value up to and including the date of first induction period dosing with CAB 30 mg plus ABC/3TC. Change from Baseline was defined as: HIV-1 RNA(log 10) at post-baseline visit minus HIV-1 RNA(log 10) at Baseline.
Time frame: At Week 32 and Week 96 (compared with Baseline [Week -20])
Absolute Value of CD4+ at Week 32 and Week 96 (Maintenance Period)
Blood samples were collected at specified time points to assess CD4+. It was evaluated by flow cytometry.
Time frame: At Week 32 and Week 96
Change From Baseline in CD4+ at Week 32 and Week 96 (Maintenance Period)
Blood samples were collected at specified time points to assess CD4+. It was evaluated by flow cytometry. Baseline (Week -20) refers to the last available value up to and including the date of first induction period dosing with CAB 30 mg plus ABC/3TC. Change from Baseline was defined as post-baseline value minus Baseline value.
Time frame: At Week 32 and Week 96 (compared with Baseline [Week -20])
Number of Participants With HIV-1 Disease Progression Over Week 32 and Week 96 (Maintenance Period)
HIV-associated conditions were recorded during the study and was assessed according to the Centers for Disease Control and Prevention (CDC) Classification System for HIV Infection in Adults. The clinical categories of HIV infection as per CDC system are class A=Asymptomatic HIV infection or lymphadenopathy or acute HIV infection; class B=symptomatic non-acquired immunodeficiency syndrome (AIDS) conditions and class C=AIDS indicator conditions. Number of participants experiencing disease progression is presented, where disease progression is defined as the progression from Baseline HIV disease status as follows: CDC class A at Baseline to CDC class C event; CDC Class B at Baseline to CDC Class C event; CDC Class C at Baseline to new CDC Class C event; and CDC class A, B or C at Baseline to death.
Time frame: At Week 32 and Week 96
Number of Participants With AEs by Their Severity Grades Over Week 32 (Maintenance Period)
An AE is any untoward medical occurrence in a clinical investigation participant, temporally associated with the use of a medicinal product, whether or not considered related to the medicinal product. Adverse events were evaluated by the investigator and graded according to the DAIDS toxicity grading, where Grade 1=Mild, 2=Moderate, 3=Severe, 4=Potentially life threatening). The higher the grade, the more severe the symptoms. Number of participants with adverse events by maximum grade have been presented.
Time frame: Up to Week 32
Number of Participants With AEs by Their Severity Grades Over Week 96 (Maintenance Period)
An AE is any untoward medical occurrence in a clinical investigation participant, temporally associated with the use of a medicinal product, whether or not considered related to the medicinal product. Adverse events were evaluated by the investigator and graded according to the DAIDS toxicity grading, where Grade 1=Mild, 2=Moderate, 3=Severe, 4=Potentially life threatening). The higher the grade, the more severe the symptoms. Number of participants with adverse events by maximum grade have been presented.
Time frame: Up to Week 96
Change From Baseline in Clinical Chemistry Parameters: ALT, ALP, AST and CK at Week 32 and Week 96 (Maintenance Period)
Blood samples were collected for the analysis of clinical chemistry parameters including ALT, ALP, AST and CK at indicated time points. Baseline (Week -20) refers to the last available value up to and including the date of first induction period dosing with CAB 30 mg plus ABC/3TC. Change from Baseline was defined as value at post-baseline visit minus value at Baseline.
Time frame: At Week 32 and Week 96 (compared with Baseline [Week -20])
Change From Baseline in Clinical Chemistry Parameter: Albumin at Week 32 and Week 96 (Maintenance Period)
Blood samples were collected for the analysis of clinical chemistry parameters including Albumin at indicated time points. Baseline (Week -20) refers to the last available value up to and including the date of first induction period dosing with CAB 30 mg plus ABC/3TC. Change from Baseline was defined as value at post-baseline visit minus value at Baseline.
Time frame: At Week 32 and Week 96 (compared with Baseline [Week -20])
Change From Baseline in Clinical Chemistry Parameters: Total Bilirubin and Creatinine at Week 32 and Week 96 (Maintenance Period)
Blood samples were collected for the analysis of clinical chemistry parameters including Total Bilirubin and Creatinine at indicated time points. Baseline (Week -20) refers to the last available value up to and including the date of first induction period dosing with CAB 30 mg plus ABC/3TC. Change from Baseline was defined as value at post-baseline visit minus value at Baseline.
Time frame: At Week 32 and Week 96 (compared with Baseline [Week -20])
Change From Baseline in Clinical Chemistry Parameters: Total CO2, Chloride, Cholesterol, Glucose, Potassium, Sodium, Triglyceride and Urea at Week 32 and Week 96 (Maintenance Period)
Blood samples were collected for the analysis of clinical chemistry parameters including total CO2, chloride, cholesterol, glucose, potassium, sodium, triglyceride and urea at indicated time points. Baseline (Week -20) refers to the last available value up to and including the date of first induction period dosing with CAB 30 mg plus ABC/3TC. Change from Baseline was defined as value at post-baseline visit minus value at Baseline.
Time frame: At Week 32 and Week 96 (compared with Baseline [Week -20])
Change From Baseline in Clinical Chemistry Parameter: Lipase at Week 32 and Week 96 (Maintenance Period)
Blood samples were collected for the analysis of clinical chemistry parameters including Lipase at indicated time points. Baseline (Week -20) refers to the last available value up to and including the date of first induction period dosing with CAB 30 mg plus ABC/3TC. Change from Baseline was defined as value at post-baseline visit minus value at Baseline.
Time frame: At Week 32 and Week 96 (compared with Baseline [Week -20])
Change From Baseline in Hematology Parameters: Basophil, Eosinophils, Lymphocytes, Total Neutrophils, Monocytes, Platelet Count and WBC Count at Week 32 and Week 96 (Maintenance Period)
Blood samples were collected for the analysis of hematology parameters including Basophil, Eosinophils, Lymphocytes, Total Neutrophils, Monocytes, Platelet count and WBC count at indicated time points. Baseline (Week -20) refers to the last available value up to and including the date of first induction period dosing with CAB 30 mg plus ABC/3TC. Change from Baseline was defined as value at post-baseline visit minus value at Baseline.
Time frame: At Week 32 and Week 96 (compared with Baseline [Week -20])
Change From Baseline in Hematology Parameter: Hematocrit at Week 32 and Week 96 (Maintenance Period)
Blood samples were collected for the analysis of hematology parameters including Hematocrit at indicated time points. Baseline (Week -20) refers to the last available value up to and including the date of first induction period dosing with CAB 30 mg plus ABC/3TC. Change from Baseline was defined as value at post-baseline visit minus value at Baseline.
Time frame: At Week 32 and Week 96 (compared with Baseline [Week -20])
Change From Baseline in Hematology Parameter: Hemoglobin at Week 32 and Week 96 (Maintenance Period)
Blood samples were collected for the analysis of hematology parameters including Hemoglobin at indicated time points. Baseline (Week -20) refers to the last available value up to and including the date of first induction period dosing with CAB 30 mg plus ABC/3TC. Change from Baseline was defined as value at post-baseline visit minus value at Baseline.
Time frame: At Week 32 and Week 96 (compared with Baseline [Week -20])
Change From Baseline in Hematology Parameter: Mean Corpuscle Volume at Week 32 and Week 96 (Maintenance Period)
Blood samples were collected for the analysis of hematology parameters including Mean Corpuscle Volume at indicated time points. Baseline (Week -20) refers to the last available value up to and including the date of first induction period dosing with CAB 30 mg plus ABC/3TC. Change from Baseline was defined as value at post-baseline visit minus value at Baseline.
Time frame: At Week 32 and Week 96 (compared with Baseline [Week -20])
Change From Baseline in Hematology Parameter: Red Blood Cell Count at Week 32 and Week 96 (Maintenance Period)
Blood samples were collected for the analysis of hematology parameters including Red Blood Cell count at indicated time points. Baseline (Week -20) refers to the last available value up to and including the date of first induction period dosing with CAB 30 mg plus ABC/3TC. Change from Baseline was defined as value at post-baseline visit minus value at Baseline.
Time frame: At Week 32 and Week 96 (compared with Baseline [Week -20])
Average Initial Concentration (C0) and Maximum Plasma Concentration (Cmax) of CAB LA (Q4W IM and Q8W IM Dosing) (Maintenance Period)
Blood samples were collected at indicated time points for pharmacokinetic (PK) analysis of CAB LA. The PK Concentration Population included all participants who received CAB LA and/or RPV LA and underwent PK sampling during the study, and provided available CAB LA and/or RPV LA plasma concentration data.
Time frame: Up to Week 32
Average Initial Concentration (C0) and Cmax of RPV LA (Q4W IM and Q8W IM Dosing) (Maintenance Period)
Blood samples were collected at indicated time points for PK analysis of RPV LA. C0 and Cmax of RPV LA (Q4W IM and Q8W IM dosing) was evaluated.
Time frame: Up to Week 32
Trough Concentration (Ctrough) of CAB LA (Q8W IM Dosing) Used for Assessment of Steady State (Maintenance Period)
Blood samples were collected at indicated time points for PK analysis of CAB LA. Ctrough is the lowest concentration reached by a drug before the next dose is administered. Ctrough for CAB LA (Q8W IM dosing) which were considered for the assessment of steady state are presented.
Time frame: Pre-dose on Weeks 16, 24 and 32
Ctrough of CAB LA (Q4W IM Dosing) Used for Assessment of Steady State (Maintenance Period)
Blood samples were collected at indicated time points for PK analysis of CAB LA. Ctrough is the lowest concentration reached by a drug before the next dose is administered. Ctrough for CAB LA (Q4W IM dosing) which were considered for the assessment of steady state are presented.
Time frame: Pre-dose on Weeks 16, 20, 24, 28 and 32
Ctrough of RPV LA (Q8W IM Dosing) Used for Assessment of Steady State (Maintenance Period)
Blood samples were collected at indicated time points for PK analysis of RPV LA. Ctrough is the lowest concentration reached by a drug before the next dose is administered. Ctrough for RPV LA (Q8W IM dosing) which were considered for the assessment of steady state are presented.
Time frame: Pre-dose on Weeks 16, 24 and 32
Ctrough of RPV LA (Q4W IM Dosing) Used for Assessment of Steady State (Maintenance Period)
Blood samples were collected at indicated time points for PK analysis of RPV LA. Ctrough is the lowest concentration reached by a drug before the next dose is administered. Ctrough for RPV LA (Q4W IM dosing) which were considered for the assessment of steady state are presented.
Time frame: Pre-dose on Weeks 16, 20, 24, 28 and 32
Pharmacodynamic Response (HIV-1 RNA<50 c/mL) in Relation With PK Parameter (AUC[0-tau]) of CAB LA and RPV LA at Week 32 (Maintenance Period)
Logistic regression was used to examine the correlation between pharmacodynamics response (HIV-1 RNA\<50 c/mL) at Week 32 and plasma PK parameter: area under plasma concentration-time curve from time zero to the end of dosing interval (AUC \[0-tau\]) of CAB LA and RPV LA per arm using MSDF (Missing, Switch or Discontinuation = Failure) algorithm. Estimates were obtained from logistic statistical model where the dependent variable is "HIV-1 RNA\<50 c/mL" (success) and the independent variable is PK parameter (AUC \[0-tau\]). Slopes and standard error are presented. Estimated effect represents the change in log odds for a one-unit increase in the PK parameter AUC (0-tau). Standard Error (SE)=0.000 is defined as following: if for all participants was resulted same value for the specific timepoint, then SE is equal with 0.000 .
Time frame: Up to Week 32
Pharmacodynamic Response (HIV-1 RNA<50 c/mL) in Relation With PK Parameter (Average C0) of CAB LA and RPV LA at Week 32 (Maintenance Period)
Logistic regression was used to examine the correlation between pharmacodynamics response (HIV-1 RNA\<50 c/mL) at Week 32 and plasma PK parameter: Average C0 of CAB LA and RPV LA per arm using MSDF (Missing, Switch or Discontinuation = Failure) algorithm. Estimates were obtained from logistic statistical model where the dependent variable is "HIV-1 RNA\<50 c/mL" (success) and the independent variable is PK parameter (Average C0). Slopes and standard error are presented. Estimated effect represents the change in log odds for a one-unit increase in the PK parameter Average C0.
Time frame: Up to Week 32
Pharmacodynamic Response (HIV-1 RNA<50 c/mL) in Relation With PK Parameter (Cmax) of CAB LA and RPV LA at Week 32 (Maintenance Period)
Logistic regression was used to examine the correlation between pharmacodynamics response (HIV-1 RNA\<50 c/mL) at Week 32 and plasma PK parameter: Cmax of CAB LA and RPV LA per arm using MSDF (Missing, Switch or Discontinuation = Failure) algorithm. Estimates were obtained from logistic statistical model where the dependent variable is "HIV-1 RNA\<50 c/mL" (success) and the independent variable is PK parameter (Cmax). Slopes and standard error are presented. Estimated effect represents the change in log odds for a one-unit increase in the PK parameter Cmax.
Time frame: Up to Week 32
Virologic Failure (From MSDF Algorithm) in Relation With PK Parameter (AUC[0-tau]) of CAB LA and RPV LA at Week 32 (Maintenance Period)
Logistic regression was used to examine the correlation between virologic failure at Week 32 and plasma PK parameter: AUC (0-tau) of CAB LA and RPV LA per arm using MSDF (Missing, Switch or Discontinuation = Failure) algorithm. Estimates were obtained from logistic statistical model where the dependent variable is "virologic failure" and the independent variable is PK parameter (AUC \[0-tau\]). Slopes and standard error are presented. Estimated effect represents the change in log odds for a one-unit increase in the PK parameter AUC (0-tau). SE=0.000 is defined as following: if for all participants was resulted same value for the specific timepoint, then SE is equal with 0.000.
Time frame: Up to Week 32
Virologic Failure (From MSDF Algorithm) in Relation With PK Parameter (Average C0) of CAB LA and RPV LA at Week 32 (Maintenance Period)
Logistic regression was used to examine the correlation between virologic failure at Week 32 and plasma PK parameter: Average C0 of CAB LA and RPV LA per arm using MSDF (Missing, Switch or Discontinuation = Failure) algorithm. Estimates were obtained from logistic statistical model where the dependent variable is "virologic failure" and the independent variable is PK parameter (Average C0). Slopes and standard error are presented. Estimated effect represents the change in log odds for a one-unit increase in the PK parameter Average C0.
Time frame: Up to Week 32
Virologic Failure (From MSDF Algorithm) in Relation With PK Parameter (Cmax) of CAB LA and RPV LA at Week 32 (Maintenance Period)
Logistic regression was used to examine the correlation between virologic failure at Week 32 and plasma PK parameter: Cmax of CAB LA and RPV LA per arm using MSDF (Missing, Switch or Discontinuation = Failure) algorithm. Estimates were obtained from logistic statistical model where the dependent variable is "virologic failure" and the independent variable is PK parameter (Cmax). Slopes and standard error are presented. Estimated effect represents the change in log odds for a one-unit increase in the PK parameter Cmax.
Time frame: Up to Week 32
Number of Participants With Treatment-emergent Genotypic Resistance
Plasma samples were collected to assess treatment emergent Genotypic Resistance for participants who had confirmed virologic failure. Number of participants who had any Integrase Inhibitor (INI) mutations or major mutations of other classes (Nucleoside reverse transcriptase inhibitor \[NRTI\], Non-nucleoside reverse transcriptase inhibitor \[NNRTI\], protease inhibitor \[PI\])are presented.
Time frame: Up to Week 32
Number of Participants With Treatment-emergent Phenotypic Resistance
Plasma samples were collected for drug resistance testing. Number of participants, with treatment emergent phenotypic resistance to INI, NNRTI, NRTI and/or PI were summarized. Overall susceptibility of the drug was categorized as sensitive, partially sensitive and resistant.
Time frame: Up to Week 32
Percentage of Participants With Plasma HIV-1 RNA Level <50 c/mL Over Week 32 by Subgroups (Maintenance Period)
Percentage of participants with HIV-1 RNA\<50 c/mL was obtained using FDA Snapshot algorithm. The algorithm treated all participants without HIV-1 RNA data at the visit of interest (due to missing data or discontinuation of investigational product prior to the visit window) as well as participants who switch their concomitant ART prior to the visit of interest, as non-responders. Data is presented for following subgroups: Baseline plasma HIV-1 RNA levels, Baseline CD4+ cell count, Race and HIV Risk factor (Homosexual contact \[HC\] and not injectable drug user).
Time frame: Up to Week 32
Percentage of Participants With Protocol Defined Virologic Failure (PDVF) at Week 32 by Subgroups(Maintenance Period)
Virologic failure was defined as any of the following: (1) Non-response as indicated by a less than a 1.0 log10 c/mL decrease in plasma HIV-1 RNA after 4 weeks of starting the Induction Period, which is subsequently confirmed, unless the plasma HIV-1 RNA is \< 400 c/mL; (2) Rebound as indicated by two consecutive plasma HIV-1 RNA levels \>=200 c/mL after prior suppression to \<200 c/mL; (3) Rebound as indicated by two consecutive plasma HIV-1 RNA that are \> 0.5 log10 c/mL increase in plasma HIV-1 RNA from the nadir value on study, where the lowest HIV-1 RNA value is \>=200 c/mL. Data is presented for following subgroups: Baseline plasma HIV-1 RNA levels, Baseline CD4+ cell count, Race and HIV Risk factor (Homosexual contact \[HC\] and not injectable drug user).
Time frame: Up to Week 32
HIV Treatment Satisfaction Questionnaire - Status Version (HIVTSQ[s]) Total Score at Week 32 and Week 96 (Maintenance Period)
The HIVTSQ(s) was developed to evaluate treatments for HIV and participant satisfaction. It has total 14 items and each items are scored from 6 (very satisfied) to 0 (very dissatisfied). Items 1 to 12 are summed to produce the Total Treatment Satisfaction Score with a possible range of 0 to 72. Higher scores represent greater treatment satisfaction as compared to the past few weeks.
Time frame: At Week 32 and Week 96
HIV Treatment Satisfaction Questionnaire - Change Version (HIVTSQ[c]) Total Score at Week 32 (Maintenance Period)
The HIVTSQ(c) was developed to evaluate treatments for HIV and participant satisfaction. It has total 14 items and each items are scored from +3 ('much more satisfied', 'much more convenient', 'much more flexible', etc.) to -3 ('much less satisfied', 'much less convenient', 'much less flexible', etc.). Items 1 to 12 (excluding Items 7b and 9b) are summed to produce a Total Treatment Satisfaction Score (change) with a possible range of -33 to +33. The higher the score, the greater the improvement in satisfaction with treatment; the lower the score, the greater the deterioration in satisfaction with treatment.
Time frame: Week 32
Number of Participants With HIV Medication Questionnaire (HIVMQ) Item E and F Scores at Week 32 (Maintenance Period)
The HIVMQ was developed to assess participant reported medication adherence. It has 6 items (a, b, c, d, e, f). Item E (How often do you find it inconvenient or difficult to take/receive medication as recommended?) and Item F (How much pain/discomfort have experienced with this medication?). Each of these 2 items are scored from 0 (none of the time) to 6 (all of the time). The higher the score, the greater the adherence to medication. Number of participants with HIVMQ Item E and F Scores at Week 32 by their score categories (0: none of the time to 6: all of the time) are presented.
Time frame: Week 32
Number of Participants With HIV Medication Questionnaire (HIVMQ) Item E and F Scores at Week 96 (Maintenance Period)
The HIVMQ was developed to assess participant reported medication adherence. It has 6 items (a, b, c, d, e, f). Item E (How often do you find it inconvenient or difficult to take/receive medication as recommended?) and Item F (How much pain/discomfort have experienced with this medication?). Each of these 2 items are scored from 0 (none of the time) to 6 (all of the time). The higher the score, the greater the adherence to medication. Number of participants with HIVMQ Item E and F Scores at Week 96 by their score categories (0: none of the time to 6: all of the time) are presented.
Time frame: Week 96
The study was conducted across 50 sites in five countries (United States, Canada, France, Germany and Spain). The results presented are based on final analysis, up to approximately Week 468.
| Milestone | CAB 30 mg+ABC/3TC QD (Induction Period) | CAB LA 600 mg+RPV LA 900 mg IM-Q8W (Maintenance and Extension Period) | CAB LA 400 mg+RPV LA 600 mg IM-Q4W (Maintenance and Extension Period) | CAB 30 mg+ABC/3TC QD (Induction Period and Maintenance Period) | Optimized CAB LA 600 mg+RPV LA 900 mg IM-Q8W (Extension Period) | Optimized CAB LA 400 mg+RPV LA 600 mg IM-Q4W (Extension Period) | Long-Term Follow-Up Group |
|---|---|---|---|---|---|---|---|
| Started | 309 | 0 | 0 | 0 | 0 | 0 | 0 |
| Completed | 288 | 0 | 0 | 0 | 0 | 0 | 0 |
| Not completed | 21 | 0 | 0 | 0 | 0 | 0 | 0 |
| Withdrew: Adverse event | 3 | 0 | 0 | 0 | 0 | 0 | 0 |
| Withdrew: Lack of efficacy | 5 | 0 | 0 | 0 | 0 | 0 | 0 |
| Withdrew: Protocol violation | 2 | 0 | 0 | 0 | 0 | 0 | 0 |
| Withdrew: Met protocol-defined stopping criteria | 3 | 0 | 0 | 0 | 0 | 0 | 0 |
| Withdrew: Lost to follow-up | 2 | 0 | 0 | 0 | 0 | 0 | 0 |
| Withdrew: Withdrawal by subject | 5 | 0 | 0 | 0 | 0 | 0 | 0 |
| Withdrew: Physician decision | 1 | 0 | 0 | 0 | 0 | 0 | 0 |
| Milestone | CAB 30 mg+ABC/3TC QD (Induction Period) | CAB LA 600 mg+RPV LA 900 mg IM-Q8W (Maintenance and Extension Period) | CAB LA 400 mg+RPV LA 600 mg IM-Q4W (Maintenance and Extension Period) | CAB 30 mg+ABC/3TC QD (Induction Period and Maintenance Period) | Optimized CAB LA 600 mg+RPV LA 900 mg IM-Q8W (Extension Period) | Optimized CAB LA 400 mg+RPV LA 600 mg IM-Q4W (Extension Period) | Long-Term Follow-Up Group |
|---|---|---|---|---|---|---|---|
| Started | 0 | 115 | 115 | 56 | 0 | 0 | 0 |
| Completed | 0 | 110 | 101 | 47 | 0 | 0 | 0 |
| Not completed | 0 | 5 | 14 | 9 | 0 | 0 | 0 |
| Withdrew: Adverse event | 0 | 1 | 8 | 1 | 0 | 0 | 0 |
| Withdrew: Lack of efficacy | 0 | 1 | 0 | 1 | 0 | 0 | 0 |
| Withdrew: Protocol violation | 0 | 1 | 2 | 0 | 0 | 0 | 0 |
| Withdrew: Met protocol-defined stopping criteria | 0 | 0 | 1 | 1 | 0 | 0 | 0 |
| Withdrew: Lost to follow-up | 0 | 0 | 0 | 1 | 0 | 0 | 0 |
| Withdrew: Withdrawal by subject | 0 | 1 | 3 | 5 | 0 | 0 | 0 |
| Withdrew: Physician decision | 0 | 1 | 0 | 0 | 0 | 0 | 0 |
| Milestone | CAB 30 mg+ABC/3TC QD (Induction Period) | CAB LA 600 mg+RPV LA 900 mg IM-Q8W (Maintenance and Extension Period) | CAB LA 400 mg+RPV LA 600 mg IM-Q4W (Maintenance and Extension Period) | CAB 30 mg+ABC/3TC QD (Induction Period and Maintenance Period) | Optimized CAB LA 600 mg+RPV LA 900 mg IM-Q8W (Extension Period) | Optimized CAB LA 400 mg+RPV LA 600 mg IM-Q4W (Extension Period) | Long-Term Follow-Up Group |
|---|---|---|---|---|---|---|---|
| Started | 0 | 107 | 101 | 0 | 34 | 10 | 0 |
| Completed | 0 | 92 | 76 | 0 | 26 | 8 | 0 |
| Not completed | 0 | 15 | 25 | 0 | 8 | 2 | 0 |
| Withdrew: Adverse event | 0 | 3 | 11 | 0 | 2 | 1 | 0 |
| Withdrew: Lack of efficacy | 0 | 0 | 0 | 0 | 1 | 0 | 0 |
| Withdrew: Protocol violation | 0 | 1 | 1 | 0 | 2 | 0 | 0 |
| Withdrew: Withdrawal by subject | 0 | 7 | 9 | 0 | 2 | 0 | 0 |
| Withdrew: Lost to follow-up | 0 | 2 | 1 | 0 | 1 | 0 | 0 |
| Withdrew: Physician decision | 0 | 2 | 2 | 0 | 0 | 0 | 0 |
| Withdrew: Site closed | 0 | 0 | 1 | 0 | 0 | 1 | 0 |
| Milestone | CAB 30 mg+ABC/3TC QD (Induction Period) | CAB LA 600 mg+RPV LA 900 mg IM-Q8W (Maintenance and Extension Period) | CAB LA 400 mg+RPV LA 600 mg IM-Q4W (Maintenance and Extension Period) | CAB 30 mg+ABC/3TC QD (Induction Period and Maintenance Period) | Optimized CAB LA 600 mg+RPV LA 900 mg IM-Q8W (Extension Period) | Optimized CAB LA 400 mg+RPV LA 600 mg IM-Q4W (Extension Period) | Long-Term Follow-Up Group |
|---|---|---|---|---|---|---|---|
| Started | 0 | 0 | 0 | 0 | 0 | 0 | 43 |
| Completed | 0 | 0 | 0 | 0 | 0 | 0 | 37 |
| Not completed | 0 | 0 | 0 | 0 | 0 | 0 | 6 |
| Withdrew: Other | 0 | 0 | 0 | 0 | 0 | 0 | 6 |
Percentage of participants with HIV-1 RNA\<50 c/mL was obtained using Food and Drug Administration (FDA) Snapshot algorithm. The algorithm treated all participants without HIV-1 RNA data at the visit of interest (due to missing data or discontinuation of investigational product prior to the visit window) as well as participants who switch their concomitant antiretroviral therapy (ART) prior to the visit of interest as non-responders. The Intent-to-Treat Maintenance Exposed (ITT-ME) Population consisted of all randomized participants who received at least one injection or one dose of investigational product during the Maintenance Period of the study (on or after Day 1 visit).
| Percentage of participants | CAB LA 600 mg+RPV LA 900 mg IM-Q8W (Maintenance and Extension Period) | CAB LA 400 mg+RPV LA 600 mg IM-Q4W (Maintenance and Extension Period) | CAB 30 mg+ABC/3TC QD (Induction Period and Maintenance Period) |
|---|---|---|---|
| Percentage of Participants With Plasma Human Immunodeficiency Virus-1 (HIV-1) Ribonucleic Acid (RNA) Level Below 50 Copies/Milliliter (c/mL) at Week 32 | 95 | 94 | 91 |
Virologic failure was defined as any of the following: (1) Non-response as indicated by a less than 1.0 logarithm to base 10 (log10) c/mL decrease in plasma HIV-1 RNA after 4 weeks of starting the Induction Period, which is subsequently confirmed, unless the plasma HIV-1 RNA is \< 400 c/mL; (2) Rebound as indicated by two consecutive plasma HIV-1 RNA levels \>=200 c/mL after prior suppression to \< 200 c/mL; (3) Rebound as indicated by two consecutive plasma HIV-1 RNA that are \> 0.5 log10 c/mL increase in plasma HIV-1 RNA from the nadir value on study, where the lowest HIV-1 RNA value is \>=200 c/mL.
| Participants | CAB LA 600 mg+RPV LA 900 mg IM-Q8W (Maintenance and Extension Period) | CAB LA 400 mg+RPV LA 600 mg IM-Q4W (Maintenance and Extension Period) | CAB 30 mg+ABC/3TC QD (Induction Period and Maintenance Period) |
|---|---|---|---|
| Number of Participants With Protocol Defined Virologic Failure (PDVF) Until Week 32 | 1 | 0 | 1 |
An AE is defined as any untoward medical occurrence in a participant or clinical investigation participant, temporally associated with the use of a medicinal product, whether or not considered related to the medicinal product. A SAE is defined as any untoward medical occurrence that, at any dose, results in death, is life threatening, requires hospitalization or prolongation of existing hospitalization, results in disability/incapacity, or is a congenital anomaly/birth defect, important medical events which may require medical or surgical intervention, drug-induced liver injury with hyperbilirubinaemia.
| Participants | CAB 30 mg+ABC/3TC QD (Induction Period) |
|---|---|
| Any non-SAE | 246 |
| Any SAE | 8 |
An AE is defined as any untoward medical occurrence in a participant or clinical investigation participant, temporally associated with the use of a medicinal product, whether or not considered related to the medicinal product. A SAE is defined as any untoward medical occurrence that, at any dose, results in death, is life threatening, requires hospitalization or prolongation of existing hospitalization, results in disability/incapacity, or is a congenital anomaly/birth defect, important medical events which may require medical or surgical intervention, drug-induced liver injury with hyperbilirubinaemia. Data presented includes all post-baseline induction period and maintenance period adverse events, as well as long-term follow-up period adverse events for those participants who did not enter the extension period.
| Participants | CAB LA 600 mg+RPV LA 900 mg IM-Q8W (Maintenance and Extension Period) | CAB LA 400 mg+RPV LA 600 mg IM-Q4W (Maintenance and Extension Period) | CAB 30 mg+ABC/3TC QD (Induction Period and Maintenance Period) |
|---|---|---|---|
| Any non-SAE | 115 | 113 | 52 |
| Any SAE | 9 | 8 | 5 |
An AE is defined as any untoward medical occurrence in a participant or clinical investigation participant, temporally associated with the use of a medicinal product, whether or not considered related to the medicinal product. Toxicity was graded according to Division of Acquired Immunodeficiency Syndrome (DAIDS) grading criteria, where Grade 1-mild, Grade 2-moderate, Grade 3-severe, Grade 4-potentially life-threatening. Data presented includes all post-baseline treatment emergent Induction Period and MP toxicities, as well as LTFP toxicities for those participants who did not enter the extension period. Number of participants with post-Baseline adverse events by maximum toxicity Grade have been presented.
| Participants | CAB LA 600 mg+RPV LA 900 mg IM-Q8W (Maintenance and Extension Period) | CAB LA 400 mg+RPV LA 600 mg IM-Q4W (Maintenance and Extension Period) | CAB 30 mg+ABC/3TC QD (Induction Period and Maintenance Period) |
|---|---|---|---|
| Any AE with maximum toxicity Grade 1 | 31 | 25 | 19 |
| Any AE with maximum toxicity Grade 2 | 67 | 72 | 29 |
| Any AE with maximum toxicity Grade 3 | 15 | 14 | 3 |
| Any AE with maximum toxicity Grade 4 | 2 | 2 | 1 |
Clinical chemistry parameters aspartate amino transferase (AST), alanine amino transferase (ALT), alkaline phosphatase (ALP), carbon dioxide(CO2) content/bicarbonate (HCO3), cholesterol, creatine kinase (CK), glucose, low density lipoprotein (LDL) cholesterol, lipase, potassium, and sodium, total bilirubin (TBIL) and triglycerides were evaluated. Toxicity was graded according to Division of Acquired Immunodeficiency Syndrome (DAIDS) grading criteria, where Grade 1-mild, Grade 2-moderate, Grade 3-severe, Grade 4-potentially life-threatening. Data presented includes all post-baseline treatment emergent Induction Period and MP toxicities, as well as LTFP toxicities for those participants who did not enter the extension period. Number of participants with any time post-baseline maximum emergent toxicities in any of the chemistry parameters have been presented.
| Participants | CAB LA 600 mg+RPV LA 900 mg IM-Q8W (Maintenance and Extension Period) | CAB LA 400 mg+RPV LA 600 mg IM-Q4W (Maintenance and Extension Period) | CAB 30 mg+ABC/3TC QD (Induction Period and Maintenance Period) |
|---|---|---|---|
| Maximum toxicity Grade 1 | 94 | 94 | 44 |
| Maximum toxicity Grade 2 | 50 | 42 | 16 |
| Maximum toxicity Grade 3 | 15 | 20 | 10 |
| Maximum toxicity Grade 4 | 10 | 7 | 2 |
Hematology parameters hemoglobin, platelet count, total neutrophils and white blood cell count were evaluated. Toxicity was graded according to DAIDS grading criteria, where Grade 1-mild, Grade 2-moderate, Grade 3-severe, Grade 4-potentially life-threatening. Data presented includes all post-baseline treatment emergent Induction Period and MP toxicities, as well as LTFP toxicities for those participants who did not enter the extension period. Number of participants with any time post-baseline maximum emergent toxicities in any of the hematology parameters have been presented.
| Participants | CAB LA 600 mg+RPV LA 900 mg IM-Q8W (Maintenance and Extension Period) | CAB LA 400 mg+RPV LA 600 mg IM-Q4W (Maintenance and Extension Period) | CAB 30 mg+ABC/3TC QD (Induction Period and Maintenance Period) |
|---|---|---|---|
| Maximum toxicity Grade 1 | 23 | 17 | 7 |
| Maximum toxicity Grade 2 | 2 | 4 | 2 |
| Maximum toxicity Grade 3 | 0 | 0 | 2 |
| Maximum toxicity Grade 4 | 0 | 3 | 0 |
Urinalysis dipstick included urine occult blood, urine glucose, urine ketones, urine nitrite, urine protein and urine leukocyte. The dipstick test gives results in a semi-quantitative manner and results for urinalysis parameters can be read as positive, trace, 1+, 2+ and 3+ indicating proportional concentrations in the urine sample. Data presented includes all post-baseline dipstick results during Induction and Maintenance Periods, as well as LTFP for those participants who did not enter the extension period.
| Participants | CAB LA 600 mg+RPV LA 900 mg IM-Q8W (Maintenance and Extension Period) | CAB LA 400 mg+RPV LA 600 mg IM-Q4W (Maintenance and Extension Period) | CAB 30 mg+ABC/3TC QD (Induction Period and Maintenance Period) |
|---|---|---|---|
| Urine Occult Blood, Trace, n=10,11,4 | 5 | 6 | 1 |
| Urine Occult Blood, 1+, n=10,11,4 | 3 | 3 | 2 |
| Urine Occult Blood, 2+, n=10,11,4 | 0 | 0 | 0 |
| Urine Occult Blood, 3+, n=10,11,4 | 2 | 2 | 1 |
| Urine Occult Blood, Positive, n=10,11,4 | 0 | 0 | 0 |
| Urine Glucose, Trace, n=1,1,1 | 1 | 0 | 0 |
| Urine Glucose, 1+, n=1,1,1 | 0 | 0 | 1 |
| Urine Glucose, 2+, n=1,1,1 | 0 | 1 | 0 |
| Urine Glucose, 3+, n=1,1,1 | 0 | 0 | 0 |
| Urine Glucose, Positive, n=1,1,1 | 0 | 0 | 0 |
| Urine Ketones, Trace, n=16,20,10 | 12 | 17 | 8 |
| Urine Ketones, 1+, n=16,20,10 | 4 | 3 | 2 |
| Urine Ketones, 2+, n=16,20,10 | 0 | 0 | 0 |
| Urine Ketones, 3+, n=16,20,10 | 0 | 0 | 0 |
| Urine Ketones, Positive, n=16,20,10 | 0 | 0 | 0 |
| Urine Nitrite, Trace, n=1,3,1 | 0 | 0 | 0 |
| Urine Nitrite, 1+, n=1,3,1 | 0 | 0 | 0 |
| Urine Nitrite, 2+, n=1,3,1 | 0 | 0 | 0 |
| Urine Nitrite, 3+, n=1,3,1 | 0 | 0 | 0 |
| Urine Nitrite, Positive, n=1,3,1 | 1 | 3 | 1 |
| Urine Protein, Trace, n=17,17,7 | 15 | 11 | 2 |
| Urine Protein, 1+, n=17,17,7 | 2 | 4 | 5 |
| Urine Protein, 2+, n=17,17,7 | 0 | 2 | 0 |
| Urine Protein, 3+, n=17,17,7 | 0 | 0 | 0 |
| Urine Protein, Positive, n=17,17,7 | 0 | 0 | 0 |
| Urine Leukocyte, Trace, n=20,20,8 | 8 | 10 | 3 |
| Urine Leukocyte, 1+, n=20,20,8 | 7 | 8 | 3 |
| Urine Leukocyte, 2+, n=20,20,8 | 4 | 0 | 1 |
| Urine Leukocyte, 3+, n=20,20,8 | 1 | 2 | 1 |
| Urine Leukocyte, Positive, n=20,20,8 | 0 | 0 | 0 |
Percentage of participants with HIV-1 RNA \<200 c/mL and \<50 c/mL for oral dose of CAB 30 mg plus ABC/3TC during Induction Period was obtained using FDA Snapshot algorithm. The algorithm treated all participants without HIV-1 RNA data at the visit of interest (due to missing data or discontinuation of investigational product prior to the visit window) as well as participants who switch their concomitant ART prior to the visit of interest, as non-responders. The Intent-to-Treat Exposed (ITT-E) Population consisted of all randomized participants who received at least one dose of investigational product.
| Percentage of participants | CAB 30 mg+ABC/3TC QD (Induction Period) |
|---|---|
| HIV-1 RNA<50 c/mL, Week -20 | 0 |
| HIV-1 RNA<50 c/mL, Week -16 | 72 |
| HIV-1 RNA<50 c/mL, Week -12 | 90 |
| HIV-1 RNA<50 c/mL, Week -8 | 89 |
| HIV-1 RNA<50 c/mL, Week -4 | 92 |
| HIV-1 RNA<50 c/mL, Day 1 | 91 |
| HIV-1 RNA<200 c/mL, Week -20 | 0 |
| HIV-1 RNA<200 c/mL, Week -16 | 94 |
| HIV-1 RNA<200 c/mL, Week -12 | 97 |
| HIV-1 RNA<200 c/mL, Week -8 | 96 |
| HIV-1 RNA<200 c/mL, Week -4 | 94 |
| HIV-1 RNA<200 c/mL, Day 1 | 94 |
Plasma samples for quantitative HIV-1 RNA were collected at indicated time points. Log10 values for HIV-1 RNA have been presented.
| Log10 copies per milliliter | CAB 30 mg+ABC/3TC QD (Induction Period) |
|---|---|
| Week -20, n=309 | 4.43 ± 0.672 |
| Week -16, n=304 | 1.71 ± 0.229 |
| Week -12, n=302 | 1.62 ± 0.108 |
| Week -8, n=299 | 1.63 ± 0.281 |
| Week -4, n=294 | 1.61 ± 0.080 |
| Day 1, n=291 | 1.60 ± 0.070 |
Plasma samples for quantitative HIV-1 RNA were collected at indicated time points. Baseline (Week -20) refers to the last available value up to and including the date of first induction period dosing with CAB 30 mg plus ABC/3TC. Change from Baseline was defined as: HIV-1 RNA(log 10) at post-baseline visit minus HIV-1 RNA(log 10) at Baseline.
| Log10 copies per milliliter | CAB 30 mg+ABC/3TC QD (Induction Period) |
|---|---|
| Week -16, n=304 | -2.72 ± 0.572 |
| Week -12, n=302 | -2.80 ± 0.640 |
| Week -8, n=299 | -2.79 ± 0.665 |
| Week -4, n=294 | -2.81 ± 0.647 |
| Day 1, n=291 | -2.82 ± 0.645 |
Blood samples were collected at specified time points to assess CD4+ using flow cytometry. Mean and standard deviation values for CD4+ are presented.
| Cells per cubic millimeter | CAB 30 mg+ABC/3TC QD (Induction Period) |
|---|---|
| Week -20, n=309 | 498.9 ± 180.67 |
| Week -16, n=304 | 630.5 ± 235.09 |
| Week -12, n=300 | 664.2 ± 256.57 |
| Week -4, n=292 | 702.3 ± 269.60 |
| Day 1, n=291 | 690.9 ± 261.63 |
Blood samples were collected at specified time points to assess CD4+. It was evaluated by flow cytometry. Baseline (Week -20) refers to the last available value up to and including the date of first induction period dosing with CAB 30 mg plus ABC/3TC. Change from Baseline was defined as value at post-baseline visit minus value at Baseline.
| Cells per cubic millimeter | CAB 30 mg+ABC/3TC QD (Induction Period) |
|---|---|
| Week -16, n=304 | 131.7 ± 172.69 |
| Week -12, n=300 | 164.5 ± 174.61 |
| Week -4, n=292 | 201.5 ± 195.53 |
| Day 1, n=291 | 188.7 ± 186.69 |
An AE is any untoward medical occurrence in a clinical investigation participant, temporally associated with the use of a medicinal product, whether or not considered related to the medicinal product. Adverse events were evaluated by the investigator and graded according to the DAIDS toxicity grading, where Grade 1=Mild, 2=Moderate, 3=Severe, 4=Potentially life threatening. The higher the grade, the more severe the symptoms. Number of participants with adverse events by maximum grade have been presented.
| Participants | CAB 30 mg+ABC/3TC QD (Induction Period) |
|---|---|
| Maximum toxicity Grade 1 | 27 |
| Maximum toxicity Grade 2 | 15 |
| Maximum toxicity Grade 3 | 2 |
| Maximum toxicity Grade 4 | 1 |
Hematology parameters hemoglobin, platelet count, total neutrophils and white blood cell count were evaluated. Laboratory toxicities were graded according to DAIDS grading criteria, where Grade 1-mild, Grade 2-moderate, Grade 3-severe, Grade 4-potentially life-threatening. Number of participants with any time post-baseline maximum emergent toxicities in any of the hematology parameters have been presented.
| Participants | CAB 30 mg+ABC/3TC QD (Induction Period) |
|---|---|
| Maximum toxicity Grade 1 | 26 |
| Maximum toxicity Grade 2 | 4 |
| Maximum toxicity Grade 3 | 1 |
| Maximum toxicity Grade 4 | 3 |
Clinical chemistry parameters AST, ALT, ALP, CO2/HCO3, cholesterol, CK, glucose, LDL cholesterol, lipase, potassium, and sodium, total TBIL and triglycerides were evaluated. Laboratory toxicities were graded according to DAIDS grading criteria, where Grade 1-mild, Grade 2-moderate, Grade 3-severe, Grade 4-potentially life-threatening. Number of participants with any time post-baseline maximum emergent toxicities in any of the chemistry parameters have been presented.
| Participants | CAB 30 mg+ABC/3TC QD (Induction Period) |
|---|---|
| Maximum toxicity Grade 1 | 130 |
| Maximum toxicity Grade 2 | 50 |
| Maximum toxicity Grade 3 | 16 |
| Maximum toxicity Grade 4 | 5 |
Blood samples were collected for the analysis of clinical chemistry parameters including ALT, ALP, AST and CK at indicated time points. Baseline (Week -20) refers to the last available value up to and including the date of first induction period dosing with CAB 30 mg plus ABC/3TC. Change from Baseline was defined as value at post-baseline visit minus value at Baseline.
| International Units per Liter (IU/L) | CAB 30 mg+ABC/3TC QD (Induction Period) |
|---|---|
| ALT, Week -16, n=306 | 0.4 ± 33.1 |
| ALT, Week -12, n=301 | -1.3 ± 14.1 |
| ALT, Week -8, n=297 | -0.5 ± 16.6 |
| ALT, Week -4, n=292 | 1.5 ± 50.3 |
| ALT, Day 1, n=287 | -1.2 ± 18.0 |
| ALP, Week -16, n=306 | -2.1 ± 12.0 |
| ALP, Week -12, n=301 | -2.6 ± 11.0 |
| ALP, Week -8, n=297 | -1.2 ± 13.0 |
| ALP, Week -4, n=292 | 0.1 ± 15.4 |
| ALP, Day 1, n=287 | 0.1 ± 14.1 |
| AST, Week -16, n=306 | 0.3 ± 33.4 |
| AST, Week -12, n=301 | -2.2 ± 13.1 |
| AST, Week -8, n=296 | -1.7 ± 15.8 |
| AST, Week -4, n=292 | -0.0 ± 30.9 |
| AST, Day 1, n=286 | -1.0 ± 25.9 |
| CK, Week -16, n=306 | 19.0 ± 345.6 |
| CK, Week -12, n=301 | 29.4 ± 485.4 |
| CK, Week -8, n=297 | 26.3 ± 529.6 |
| CK, Week -4, n=292 | 33.2 ± 434.2 |
| CK, Day 1, n=287 | 69.9 ± 1164.7 |
Blood samples were collected for the analysis of clinical chemistry parameter: Albumin at indicated time points. Baseline (Week -20) refers to the last available value up to and including the date of first induction period dosing with CAB 30 mg plus ABC/3TC. Change from Baseline was defined as value at post-baseline visit minus value at Baseline.
| Grams per Liter (G/L) | CAB 30 mg+ABC/3TC QD (Induction Period) |
|---|---|
| Week -16, n=306 | 0.2 ± 2.3 |
| Week -12, n=301 | 0.7 ± 2.3 |
| Week -8, n=297 | 1.4 ± 2.6 |
| Week -4, n=292 | 1.7 ± 2.6 |
| Day 1, n=287 | 1.9 ± 2.8 |
Blood samples were collected for the analysis of clinical chemistry parameters including total Bilirubin and Creatinine at indicated time points. Baseline (Week -20) refers to the last available value up to and including the date of first induction period dosing with CAB 30 mg plus ABC/3TC. Change from Baseline was defined as value at post-baseline visit minus value at Baseline.
| Micromoles per Liter (umol/L) | CAB 30 mg+ABC/3TC QD (Induction Period) |
|---|---|
| Total Bilirubin, Week -16, n=305 | -0.6 ± 4.5 |
| Total Bilirubin, Week -12, n=301 | -0.9 ± 4.0 |
| Total Bilirubin, Week -8, n=297 | -1.0 ± 4.1 |
| Total Bilirubin, Week -4, n=292 | -0.5 ± 4.1 |
| Total Bilirubin, Day 1, n=287 | -0.3 ± 4.0 |
| Creatinine, Week -16, n=306 | 2.6 ± 7.6 |
| Creatinine, Week -12, n=301 | 1.5 ± 7.8 |
| Creatinine, Week -8, n=297 | 1.6 ± 7.8 |
| Creatinine, Week -4, n=292 | 3.5 ± 8.7 |
| Creatinine, Day 1, n=287 | 4.6 ± 9.1 |
Blood samples were collected for the analysis of clinical chemistry parameters including total CO2, chloride, cholesterol, glucose, potassium, sodium, triglyceride and urea at indicated time points. Baseline (Week -20) refers to the last available value up to and including the date of first induction period dosing with CAB 30 mg plus ABC/3TC. Change from Baseline was defined as value at post-baseline visit minus value at Baseline.
| Millimoles per Liter (mmol/L) | CAB 30 mg+ABC/3TC QD (Induction Period) |
|---|---|
| CO2, Week -16, n=306 | 0.2 ± 2.4 |
| CO2, Week -12, n=301 | 0.3 ± 2.3 |
| CO2, Week -8, n=296 | 0.4 ± 2.3 |
| CO2, Week -4, n=292 | 0.1 ± 2.3 |
| CO2, Day 1, n=286 | -0.8 ± 2.6 |
| Chloride, Week -16, n=306 | 0.2 ± 2.3 |
| Chloride, Week -12, n=301 | 0.5 ± 2.2 |
| Chloride, Week -8, n=297 | 0.6 ± 2.3 |
| Chloride, Week -4, n=292 | 0.2 ± 2.3 |
| Chloride, Day 1, n=287 | 0.2 ± 2.3 |
| Cholesterol, Week -16, n=255 | 0.21 ± 0.6 |
| Cholesterol, Week -12, n=236 | 0.19 ± 0.5 |
| Cholesterol, Week -8, n=235 | 0.27 ± 0.5 |
| Cholesterol, Week -4, n=282 | 0.34 ± 0.5 |
| Cholesterol, Day 1, n=285 | 0.34 ± 0.6 |
| Glucose, Week -16, n=255 | 0.07 ± 0.7 |
| Glucose, Week -12, n=236 | 0.16 ± 0.7 |
| Glucose, Week -8, n=235 | 0.08 ± 0.7 |
| Glucose, Week -4, n=281 | 0.06 ± 0.7 |
| Glucose, Day 1, n=282 | -0.01 ± 0.7 |
| Potassium, Week -16, n=306 | -0.05 ± 0.2 |
| Potassium, Week -12, n=301 | -0.03 ± 0.3 |
| Potassium, Week -8, n=296 | 0.03 ± 0.3 |
| Potassium, Week -4, n=292 | 0.03 ± 0.3 |
| Potassium, Day 1, n=286 | 0.03 ± 0.3 |
| Sodium, Week -16, n=306 | -0.1 ± 1.8 |
| Sodium, Week -12, n=301 | 0.1 ± 1.8 |
| Sodium, Week -8, n=297 | 0.2 ± 1.9 |
| Sodium, Week -4, n=292 | 0.4 ± 2.0 |
| Sodium, Day 1, n=287 | 0.3 ± 1.9 |
| Triglyceride, Week -16, n=3 | -0.69 ± 0.1 |
| Triglyceride, Week -12, n=2 | -0.37 ± 0.1 |
| Triglyceride, Week -8, n=2 | 0.29 ± 0.4 |
| Triglyceride, Week -4, n=278 | 0.20 ± 0.9 |
| Triglyceride, Day 1, n=278 | -0.00 ± 0.7 |
| Urea, Week -16, n=306 | -0.06 ± 1.2 |
| Urea, Week -12, n=301 | -0.08 ± 1.2 |
| Urea, Week -8, n=297 | -0.09 ± 1.1 |
| Urea, Week -4, n=292 | -0.12 ± 1.3 |
| Urea, Day 1, n=287 | 0.00 ± 1.2 |
Blood samples were collected for the analysis of clinical chemistry parameter: Lipase at indicated time points. Baseline (Week -20) refers to the last available value up to and including the date of first induction period dosing with CAB 30 mg plus ABC/3TC. Change from Baseline was defined as value at post-baseline visit minus value at Baseline.
| Units per Liter (U/L) | CAB 30 mg+ABC/3TC QD (Induction Period) |
|---|---|
| Week -16, n=306 | 3.3 ± 20.0 |
| Week -12, n=301 | 0.8 ± 15.3 |
| Week -8, n=297 | 2.8 ± 24.3 |
| Week -4, n=292 | 2.1 ± 23.8 |
| Day 1, n=288 | -1.2 ± 17.7 |
Blood samples were collected for the analysis of hematology parameters: Basophil, Eosinophils, Lymphocytes, Total Neutrophils, Monocytes, Platelets count and WBC at indicated time points. Baseline (Week -20) refers to the last available value up to and including the date of first induction period dosing with CAB 30 mg plus ABC/3TC. Change from Baseline was defined as value at post-baseline visit minus value at Baseline.
| Giga cells per Liter | CAB 30 mg+ABC/3TC QD (Induction Period) |
|---|---|
| Basophils, Week -16, n=303 | 0.00 ± 0.016 |
| Basophils, Week -12, n=298 | 0.00 ± 0.019 |
| Basophils, Week -8, n=297 | 0.00 ± 0.015 |
| Basophils, Week -4, n=290 | 0.00 ± 0.016 |
| Basophils, Day 1, n=290 | 0.00 ± 0.019 |
| Eosinophils, Week -16, n=303 | 0.01 ± 0.131 |
| Eosinophils, Week -12, n=298 | 0.01 ± 0.123 |
| Eosinophils, Week -8, n=297 | 0.02 ± 0.127 |
| Eosinophils, Week -4, n=290 | 0.02 ± 0.136 |
| Eosinophils, Day 1, n=290 | 0.03 ± 0.161 |
| Lymphocytes, Week -16, n=303 | 0.24 ± 0.541 |
| Lymphocytes, Week -12, n=298 | 0.28 ± 0.573 |
| Lymphocytes, Week -8, n=297 | 0.30 ± 0.541 |
| Lymphocytes, Week -4, n=290 | 0.30 ± 0.574 |
| Lymphocytes, Day 1, n=290 | 0.14 ± 0.565 |
| Monocytes, Week -16, n=303 | -0.00 ± 0.129 |
| Monocytes, Week -12, n=298 | 0.00 ± 0.139 |
| Monocytes, Week -8, n=297 | -0.00 ± 0.135 |
| Monocytes, Week -4, n=290 | -0.00 ± 0.132 |
| Monocytes, Day 1, n=290 | 0.00 ± 0.143 |
| Platelet count, Week -16, n=302 | 14.4 ± 31.56 |
| Platelet count, Week -12, n=300 | 18.2 ± 32.53 |
| Platelet count, Week -8, n=297 | 21.1 ± 37.00 |
| Platelet count, Week -4, n=290 | 23.0 ± 35.02 |
| Platelet count, Day 1, n=290 | 22.2 ± 35.32 |
| Total Neutrophils, Week -16, n=303 | 0.04 ± 1.185 |
| Total Neutrophils, Week -12, n=298 | 0.22 ± 1.391 |
| Total Neutrophils, Week -8, n=297 | 0.20 ± 1.286 |
| Total Neutrophils, Week -4, n=290 | 0.31 ± 1.429 |
| Total Neutrophils, Day 1, n=290 | 0.38 ± 1.515 |
| WBC, Week -16, n=303 | 0.31 ± 1.318 |
| WBC, Week -12, n=298 | 0.52 ± 1.522 |
| WBC, Week -8, n=297 | 0.54 ± 1.460 |
| WBC, Week -4, n=290 | 0.64 ± 1.594 |
| WBC, Day 1, n=290 | 0.57 ± 1.713 |
Blood samples were collected for the analysis of hematology parameter: Hematocrit at indicated time points. Baseline (Week -20) refers to the last available value up to and including the date of first induction period dosing with CAB 30 mg plus ABC/3TC. Change from Baseline was defined as value at post-baseline visit minus value at Baseline.
| Proportion of red blood cells in blood | CAB 30 mg+ABC/3TC QD (Induction Period) |
|---|---|
| Week -16, n=304 | 0.00 ± 0.022 |
| Week -12, n=302 | 0.00 ± 0.023 |
| Week -8, n=298 | 0.00 ± 0.024 |
| Week -4, n=290 | 0.00 ± 0.025 |
| Day 1, n=290 | 0.00 ± 0.025 |
Blood samples were collected for the analysis of hematology parameter: Hemoglobin at indicated time points. Baseline (Week -20) refers to the last available value up to and including the date of first induction period dosing with CAB 30 mg plus ABC/3TC. Change from Baseline was defined as value at post-baseline visit minus value at Baseline.
| Grams per Liter | CAB 30 mg+ABC/3TC QD (Induction Period) |
|---|---|
| Week -16, n=304 | 0.8 ± 6.94 |
| Week -12, n=302 | 2.0 ± 7.07 |
| Week -8, n=298 | 2.5 ± 7.42 |
| Week -4, n=290 | 3.3 ± 7.95 |
| Day 1, n=290 | 3.1 ± 7.96 |
Blood samples were collected for the analysis of hematology parameter: Mean Corpuscle Volume at indicated time points. Baseline (Week -20) refers to the last available value up to and including the date of first induction period dosing with CAB 30 mg plus ABC/3TC. Change from Baseline was defined as value at post-baseline visit minus value at Baseline.
| Femtoliters | CAB 30 mg+ABC/3TC QD (Induction Period) |
|---|---|
| Week -16, n=304 | 1.0 ± 1.52 |
| Week -12, n=302 | 2.1 ± 1.90 |
| Week -8, n=298 | 3.1 ± 2.49 |
| Week -4, n=290 | 4.0 ± 2.47 |
| Day 1, n=290 | 4.4 ± 2.57 |
Blood samples were collected for the analysis of hematology parameter: Red Blood Cell count at indicated time points. Baseline (Week -20) refers to the last available value up to and including the date of first induction period dosing with CAB 30 mg plus ABC/3TC. Change from Baseline was defined as value at post-baseline visit minus value at Baseline.
| 10^12 cells per Liter | CAB 30 mg+ABC/3TC QD (Induction Period) |
|---|---|
| Week -16, n=304 | -0.05 ± 0.242 |
| Week -12, n=302 | -0.07 ± 0.254 |
| Week -8, n=298 | -0.10 ± 0.266 |
| Week -4, n=290 | -0.10 ± 0.284 |
| Day 1, n=290 | -0.14 ± 0.289 |
Percentage of participants with HIV-1 RNA \<50 c/mL and \<200 c/mL was obtained using FDA Snapshot algorithm. The algorithm treated all participants without HIV-1 RNA data at the visit of interest (due to missing data or discontinuation of investigational product prior to the visit window) as well as participants who switch their concomitant ART prior to the visit of interest, as non-responders.
| Percentage of participants | CAB LA 600 mg+RPV LA 900 mg IM-Q8W (Maintenance and Extension Period) | CAB LA 400 mg+RPV LA 600 mg IM-Q4W (Maintenance and Extension Period) | CAB 30 mg+ABC/3TC QD (Induction Period and Maintenance Period) |
|---|---|---|---|
| HIV-1 RNA<50 c/mL, Day 1 | 95 | 99 | 98 |
| HIV-1 RNA<50 c/mL, Week 4 | 97 | 98 | 93 |
| HIV-1 RNA<50 c/mL, Week 8 | 98 | 97 | 95 |
| HIV-1 RNA<50 c/mL, Week 12 | 96 | 97 | 98 |
| HIV-1 RNA<50 c/mL, Week 16 | 97 | 96 | 89 |
| HIV-1 RNA<50 c/mL, Week 20 | 97 | 97 | 91 |
| HIV-1 RNA<50 c/mL, Week 24 | 96 | 94 | 91 |
| HIV-1 RNA<50 c/mL, Week 28 | 90 | 92 | 86 |
| HIV-1 RNA<50 c/mL, Week 32 | 95 | 94 | 91 |
| HIV-1 RNA<50 c/mL, Week 36 | 95 | 90 | 88 |
| HIV-1 RNA<50 c/mL, Week 40 | 92 | 91 | 86 |
| HIV-1 RNA<50 c/mL, Week 44 | 93 | 90 | 88 |
| HIV-1 RNA<50 c/mL, Week 48 | 92 | 91 | 89 |
| HIV-1 RNA<50 c/mL, Week 56 | 94 | 90 | 84 |
| HIV-1 RNA<50 c/mL, Week 64 | 95 | 90 | 86 |
| HIV-1 RNA<50 c/mL, Week 72 | 95 | 90 | 88 |
| HIV-1 RNA<50 c/mL, Week 80 | 95 | 87 | 84 |
| HIV-1 RNA<50 c/mL, Week 88 | 95 | 86 | 84 |
| HIV-1 RNA<50 c/mL, Week 96 | 94 | 87 | 84 |
| HIV-1 RNA<200 c/mL, Day 1 | 100 | 100 | 98 |
| HIV-1 RNA<200 c/mL, Week 4 | 99 | 100 | 96 |
| HIV-1 RNA<200 c/mL, Week 8 | 99 | 99 | 95 |
| HIV-1 RNA<200 c/mL, Week 12 | 97 | 98 | 98 |
| HIV-1 RNA<200 c/mL, Week 16 | 98 | 98 | 93 |
| HIV-1 RNA<200 c/mL, Week 20 | 98 | 97 | 93 |
| HIV-1 RNA<200 c/mL, Week 24 | 97 | 96 | 93 |
| HIV-1 RNA<200 c/mL, Week 28 | 94 | 95 | 91 |
| HIV-1 RNA<200 c/mL, Week 32 | 97 | 95 | 91 |
| HIV-1 RNA<200 c/mL, Week 36 | 97 | 93 | 89 |
| HIV-1 RNA<200 c/mL, Week 40 | 97 | 92 | 86 |
| HIV-1 RNA<200 c/mL, Week 44 | 95 | 91 | 89 |
| HIV-1 RNA<200 c/mL, Week 48 | 97 | 92 | 89 |
| HIV-1 RNA<200 c/mL, Week 56 | 96 | 90 | 86 |
| HIV-1 RNA<200 c/mL, Week 64 | 96 | 90 | 88 |
| HIV-1 RNA<200 c/mL, Week 72 | 96 | 90 | 88 |
| HIV-1 RNA<200 c/mL, Week 80 | 96 | 88 | 84 |
| HIV-1 RNA<200 c/mL, Week 88 | 96 | 86 | 84 |
| HIV-1 RNA<200 c/mL, Week 96 | 96 | 87 | 84 |
Virologic failure was defined as any of the following: (1) Non-response as indicated by a less than a 1.0 log10 c/mL decrease in plasma HIV-1 RNA after 4 weeks of starting the Induction Period, which is subsequently confirmed, unless the plasma HIV-1 RNA is \< 400 c/mL; (2) Rebound as indicated by two consecutive plasma HIV-1 RNA levels \>=200 c/mL after prior suppression to \< 200 c/mL; (3) Rebound as indicated by two consecutive plasma HIV-1 RNA that are \> 0.5 log10 c/mL increase in plasma HIV-1 RNA from the nadir value on study, where the lowest HIV-1 RNA value is \>=200 c/mL.
| Participants | CAB LA 600 mg+RPV LA 900 mg IM-Q8W (Maintenance and Extension Period) | CAB LA 400 mg+RPV LA 600 mg IM-Q4W (Maintenance and Extension Period) | CAB 30 mg+ABC/3TC QD (Induction Period and Maintenance Period) |
|---|---|---|---|
| Week 32 | 1 | 0 | 1 |
| Week 48 | 2 | 0 | 1 |
Plasma samples for quantitative HIV-1 RNA analysis were collected at indicated time points during Maintenance Period. Log10 values for HIV-1 RNA have been presented. SD=0.000 is defined as following: if participants analyzed at a specific timepoint have resulted same values, then SD is considered equal with 0.000.
| Log10 copies per milliliter | CAB LA 600 mg+RPV LA 900 mg IM-Q8W (Maintenance and Extension Period) | CAB LA 400 mg+RPV LA 600 mg IM-Q4W (Maintenance and Extension Period) | CAB 30 mg+ABC/3TC QD (Induction Period and Maintenance Period) |
|---|---|---|---|
| Week 32 | 1.60 ± 0.044 | 1.59 ± 0.025 | 1.61 ± 0.112 |
| Week 96 | 1.60 ± 0.056 | 1.59 ± 0.000 | 1.59 ± 0.000 |
Plasma samples for quantitative HIV-1 RNA analysis were collected at indicated time points during Maintenance Period. Baseline (Week -20) refers to the last available value up to and including the date of first induction period dosing with CAB 30 mg plus ABC/3TC. Change from Baseline was defined as: HIV-1 RNA(log 10) at post-baseline visit minus HIV-1 RNA(log 10) at Baseline.
| Log10 copies per milliliter | CAB LA 600 mg+RPV LA 900 mg IM-Q8W (Maintenance and Extension Period) | CAB LA 400 mg+RPV LA 600 mg IM-Q4W (Maintenance and Extension Period) | CAB 30 mg+ABC/3TC QD (Induction Period and Maintenance Period) |
|---|---|---|---|
| Week 32 | -2.78 ± 0.610 | -2.88 ± 0.709 | -2.73 ± 0.561 |
| Week 96 | -2.77 ± 0.602 | -2.89 ± 0.713 | -2.77 ± 0.582 |
Blood samples were collected at specified time points to assess CD4+. It was evaluated by flow cytometry.
| Cells per cubic millimeter | CAB LA 600 mg+RPV LA 900 mg IM-Q8W (Maintenance and Extension Period) | CAB LA 400 mg+RPV LA 600 mg IM-Q4W (Maintenance and Extension Period) | CAB 30 mg+ABC/3TC QD (Induction Period and Maintenance Period) |
|---|---|---|---|
| Week 32 | 752.3 ± 318.02 | 761.3 ± 293.07 | 891.3 ± 273.32 |
| Week 96 | 748.6 ± 253.41 | 750.0 ± 271.11 | 906.8 ± 288.77 |
Blood samples were collected at specified time points to assess CD4+. It was evaluated by flow cytometry. Baseline (Week -20) refers to the last available value up to and including the date of first induction period dosing with CAB 30 mg plus ABC/3TC. Change from Baseline was defined as post-baseline value minus Baseline value.
| Cells per cubic millimeter | CAB LA 600 mg+RPV LA 900 mg IM-Q8W (Maintenance and Extension Period) | CAB LA 400 mg+RPV LA 600 mg IM-Q4W (Maintenance and Extension Period) | CAB 30 mg+ABC/3TC QD (Induction Period and Maintenance Period) |
|---|---|---|---|
| Week 32 | 264.4 ± 247.84 | 263.7 ± 217.74 | 346.1 ± 219.59 |
| Week 96 | 257.5 ± 192.25 | 270.6 ± 210.99 | 369.9 ± 226.60 |
HIV-associated conditions were recorded during the study and was assessed according to the Centers for Disease Control and Prevention (CDC) Classification System for HIV Infection in Adults. The clinical categories of HIV infection as per CDC system are class A=Asymptomatic HIV infection or lymphadenopathy or acute HIV infection; class B=symptomatic non-acquired immunodeficiency syndrome (AIDS) conditions and class C=AIDS indicator conditions. Number of participants experiencing disease progression is presented, where disease progression is defined as the progression from Baseline HIV disease status as follows: CDC class A at Baseline to CDC class C event; CDC Class B at Baseline to CDC Class C event; CDC Class C at Baseline to new CDC Class C event; and CDC class A, B or C at Baseline to death.
| Participants | CAB LA 600 mg+RPV LA 900 mg IM-Q8W (Maintenance and Extension Period) | CAB LA 400 mg+RPV LA 600 mg IM-Q4W (Maintenance and Extension Period) | CAB 30 mg+ABC/3TC QD (Induction Period and Maintenance Period) |
|---|---|---|---|
| From CDC Stage 1 to CDC Stage 3 Event, Week 32 | 1 | 0 | 0 |
| From CDC Stage 2 to CDC Stage 3 Event, Week 32 | 0 | 0 | 0 |
| From CDC Stage 3 to New CDC Stage 3 Event, Week 32 | 0 | 0 | 0 |
| From CDC Stage 1, 2 or 3 to Death, Week 32 | 0 | 1 | 0 |
| From CDC Stage 1 to CDC Stage 3 Event, Week 96 | 4 | 0 | 0 |
| From CDC Stage 2 to CDC Stage 3 Event, Week 96 | 0 | 0 | 0 |
| From CDC Stage 3 to New CDC Stage 3 Event, Week 96 | 0 | 0 | 0 |
| From CDC Stage 1, 2 or 3 to Death, Week 96 | 0 | 1 | 0 |
An AE is any untoward medical occurrence in a clinical investigation participant, temporally associated with the use of a medicinal product, whether or not considered related to the medicinal product. Adverse events were evaluated by the investigator and graded according to the DAIDS toxicity grading, where Grade 1=Mild, 2=Moderate, 3=Severe, 4=Potentially life threatening). The higher the grade, the more severe the symptoms. Number of participants with adverse events by maximum grade have been presented.
| Participants | CAB LA 600 mg+RPV LA 900 mg IM-Q8W (Maintenance and Extension Period) | CAB LA 400 mg+RPV LA 600 mg IM-Q4W (Maintenance and Extension Period) | CAB 30 mg+ABC/3TC QD (Induction Period and Maintenance Period) |
|---|---|---|---|
| Grade 1 | 35 | 29 | 23 |
| Grade 2 | 65 | 69 | 22 |
| Grade 3 | 14 | 13 | 1 |
| Grade 4 | 1 | 2 | 0 |
An AE is any untoward medical occurrence in a clinical investigation participant, temporally associated with the use of a medicinal product, whether or not considered related to the medicinal product. Adverse events were evaluated by the investigator and graded according to the DAIDS toxicity grading, where Grade 1=Mild, 2=Moderate, 3=Severe, 4=Potentially life threatening). The higher the grade, the more severe the symptoms. Number of participants with adverse events by maximum grade have been presented.
| Participants | CAB LA 600 mg+RPV LA 900 mg IM-Q8W (Maintenance and Extension Period) | CAB LA 400 mg+RPV LA 600 mg IM-Q4W (Maintenance and Extension Period) | CAB 30 mg+ABC/3TC QD (Induction Period and Maintenance Period) |
|---|---|---|---|
| Grade 1 | 23 | 21 | 24 |
| Grade 2 | 71 | 74 | 26 |
| Grade 3 | 19 | 18 | 4 |
| Grade 4 | 2 | 2 | 0 |
Blood samples were collected for the analysis of clinical chemistry parameters including ALT, ALP, AST and CK at indicated time points. Baseline (Week -20) refers to the last available value up to and including the date of first induction period dosing with CAB 30 mg plus ABC/3TC. Change from Baseline was defined as value at post-baseline visit minus value at Baseline.
| International Units per Liter | CAB LA 600 mg+RPV LA 900 mg IM-Q8W (Maintenance and Extension Period) | CAB LA 400 mg+RPV LA 600 mg IM-Q4W (Maintenance and Extension Period) | CAB 30 mg+ABC/3TC QD (Induction Period and Maintenance Period) |
|---|---|---|---|
| ALT, Week 32 | -2.4 ± 13.4 | -2.7 ± 13.5 | -5.0 ± 19.5 |
| ALP, Week 32 | -1.2 ± 14.6 | -3.8 ± 15.0 | -1.3 ± 11.6 |
| AST, Week 32 | -2.8 ± 12.5 | -2.2 ± 14.5 | -8.3 ± 30.6 |
| CK, Week 32 | 51.4 ± 651.0 | 93.4 ± 446.9 | 38.8 ± 394.9 |
| ALT, Week 96 | 1.8 ± 19.19 | -2.2 ± 14.42 | -2.7 ± 22.17 |
| ALP, Week 96 | -3.1 ± 15.59 | -3.4 ± 15.64 | -2.8 ± 12.34 |
| AST, Week 96 | -1.0 ± 15.45 | -4.0 ± 9.31 | -8.8 ± 32.57 |
| CK, Week 96 | 21.1 ± 490.00 | 13.7 ± 153.92 | -13.9 ± 227.98 |
Blood samples were collected for the analysis of clinical chemistry parameters including Albumin at indicated time points. Baseline (Week -20) refers to the last available value up to and including the date of first induction period dosing with CAB 30 mg plus ABC/3TC. Change from Baseline was defined as value at post-baseline visit minus value at Baseline.
| Grams per Liter | CAB LA 600 mg+RPV LA 900 mg IM-Q8W (Maintenance and Extension Period) | CAB LA 400 mg+RPV LA 600 mg IM-Q4W (Maintenance and Extension Period) | CAB 30 mg+ABC/3TC QD (Induction Period and Maintenance Period) |
|---|---|---|---|
| Week 32 | 1.4 ± 3.0 | 0.9 ± 2.9 | 1.1 ± 2.8 |
| Week 96 | 1.0 ± 2.76 | 0.9 ± 2.87 | 0.2 ± 2.61 |
Blood samples were collected for the analysis of clinical chemistry parameters including Total Bilirubin and Creatinine at indicated time points. Baseline (Week -20) refers to the last available value up to and including the date of first induction period dosing with CAB 30 mg plus ABC/3TC. Change from Baseline was defined as value at post-baseline visit minus value at Baseline.
| Micromoles per Liter | CAB LA 600 mg+RPV LA 900 mg IM-Q8W (Maintenance and Extension Period) | CAB LA 400 mg+RPV LA 600 mg IM-Q4W (Maintenance and Extension Period) | CAB 30 mg+ABC/3TC QD (Induction Period and Maintenance Period) |
|---|---|---|---|
| Total Bilirubin, Week 32 | 0.8 ± 4.4 | 0.4 ± 3.6 | -0.6 ± 4.4 |
| Creatinine, Week 32 | 2.7 ± 8.5 | 3.8 ± 8.7 | 2.7 ± 6.1 |
| Total Bilirubin, Week 96 | 0.0 ± 3.78 | -0.3 ± 4.11 | -1.1 ± 4.25 |
| Creatinine, Week 96 | 3.11 ± 8.515 | 4.27 ± 8.730 | 4.42 ± 6.105 |
Blood samples were collected for the analysis of clinical chemistry parameters including total CO2, chloride, cholesterol, glucose, potassium, sodium, triglyceride and urea at indicated time points. Baseline (Week -20) refers to the last available value up to and including the date of first induction period dosing with CAB 30 mg plus ABC/3TC. Change from Baseline was defined as value at post-baseline visit minus value at Baseline.
| Millimoles per Liter | CAB LA 600 mg+RPV LA 900 mg IM-Q8W (Maintenance and Extension Period) | CAB LA 400 mg+RPV LA 600 mg IM-Q4W (Maintenance and Extension Period) | CAB 30 mg+ABC/3TC QD (Induction Period and Maintenance Period) |
|---|---|---|---|
| Total CO2, Week 32 | -0.8 ± 2.1 | -1.5 ± 2.4 | -1.1 ± 2.4 |
| Chloride, Week 32 | -0.2 ± 2.2 | -0.3 ± 2.4 | 0.1 ± 2.1 |
| Cholesterol, Week 32 | 0.37 ± 0.6 | 0.47 ± 0.7 | 0.25 ± 0.5 |
| Glucose, Week 32 | 0.13 ± 1.0 | 0.03 ± 0.7 | -0.05 ± 0.6 |
| Potassium, Week 32 | 0.01 ± 0.3 | -0.05 ± 0.3 | -0.04 ± 0.2 |
| Sodium, Week 32 | 0.4 ± 2.0 | -0.1 ± 1.8 | 0.0 ± 1.7 |
| Triglycerides, Week 32 | 0.08 ± 0.9 | -0.00 ± 1.7 | 0.06 ± 0.7 |
| Urea, Week 32 | 0.15 ± 1.3 | 0.23 ± 1.4 | -0.01 ± 1.4 |
| Total CO2, Week 96 | -0.8 ± 2.88 | -1.1 ± 2.64 | -0.1 ± 2.47 |
| Chloride, Week 96 | -0.1 ± 2.32 | -0.4 ± 2.53 | 0.3 ± 2.12 |
| Cholesterol, Week 96 | 0.554 ± 0.6724 | 0.731 ± 0.7380 | 0.348 ± 0.6490 |
| Glucose, Week 96 | 0.12 ± 0.729 | 0.11 ± 0.667 | 0.02 ± 0.745 |
| Potassium, Week 96 | 0.11 ± 0.378 | -0.04 ± 0.408 | -0.03 ± 0.314 |
| Sodium, Week 96 | -0.1 ± 1.85 | -0.4 ± 2.07 | -0.4 ± 1.96 |
| Triglycerides, Week 96 | 0.084 ± 0.9000 | 0.080 ± 1.4964 | 0.197 ± 0.4972 |
| Urea, Week 96 | 0.09 ± 1.393 | -0.01 ± 1.230 | 0.12 ± 1.461 |
Blood samples were collected for the analysis of clinical chemistry parameters including Lipase at indicated time points. Baseline (Week -20) refers to the last available value up to and including the date of first induction period dosing with CAB 30 mg plus ABC/3TC. Change from Baseline was defined as value at post-baseline visit minus value at Baseline.
| Units per Liter | CAB LA 600 mg+RPV LA 900 mg IM-Q8W (Maintenance and Extension Period) | CAB LA 400 mg+RPV LA 600 mg IM-Q4W (Maintenance and Extension Period) | CAB 30 mg+ABC/3TC QD (Induction Period and Maintenance Period) |
|---|---|---|---|
| Week 32 | -1.2 ± 33.2 | -4.4 ± 15.4 | -3.9 ± 14.7 |
| Week 96 | 3.5 ± 22.00 | -0.8 ± 14.73 | -2.3 ± 14.21 |
Blood samples were collected for the analysis of hematology parameters including Basophil, Eosinophils, Lymphocytes, Total Neutrophils, Monocytes, Platelet count and WBC count at indicated time points. Baseline (Week -20) refers to the last available value up to and including the date of first induction period dosing with CAB 30 mg plus ABC/3TC. Change from Baseline was defined as value at post-baseline visit minus value at Baseline.
| 10^9 cells per Liter | CAB LA 600 mg+RPV LA 900 mg IM-Q8W (Maintenance and Extension Period) | CAB LA 400 mg+RPV LA 600 mg IM-Q4W (Maintenance and Extension Period) | CAB 30 mg+ABC/3TC QD (Induction Period and Maintenance Period) |
|---|---|---|---|
| Basophils, Week 32 | 0.00 ± 0.012 | -0.00 ± 0.022 | 0.00 ± 0.010 |
| Eosinophils, Week 32 | 0.01 ± 0.146 | 0.23 ± 1.985 | -0.01 ± 0.143 |
| Lymphocytes, Week 32 | 0.34 ± 0.661 | 0.26 ± 0.694 | 0.48 ± 0.635 |
| Monocytes, Week 32 | -0.02 ± 0.152 | -0.03 ± 0.144 | -0.00 ± 0.144 |
| Platelet count, Week 32 | 18.7 ± 38.28 | 20.6 ± 44.93 | 11.6 ± 33.33 |
| Total Neutrophils, Week 32 | 0.59 ± 1.505 | 0.34 ± 1.489 | 0.94 ± 1.365 |
| WBC count, Week 32 | 0.93 ± 1.670 | 0.81 ± 2.881 | 1.41 ± 1.529 |
| Basophils, Week 96 | 0.004 ± 0.0139 | 0.000 ± 0.0204 | 0.006 ± 0.0157 |
| Eosinophils, Week 96 | 0.015 ± 0.1461 | 0.021 ± 0.1013 | -0.013 ± 0.1528 |
| Lymphocytes, Week 96 | 0.325 ± 0.6356 | 0.290 ± 0.6793 | 0.534 ± 0.5408 |
| Monocytes, Week 96 | -0.009 ± 0.1685 | -0.014 ± 0.1781 | -0.005 ± 0.1443 |
| Platelet count, Week 96 | 21.9 ± 40.07 | 21.1 ± 41.49 | 15.3 ± 39.28 |
| Total Neutrophils, Week 96 | 0.381 ± 1.3060 | 0.515 ± 1.6200 | 0.783 ± 1.0747 |
| WBC count, Week 96 | 0.72 ± 1.545 | 0.82 ± 1.786 | 1.31 ± 1.144 |
Blood samples were collected for the analysis of hematology parameters including Hematocrit at indicated time points. Baseline (Week -20) refers to the last available value up to and including the date of first induction period dosing with CAB 30 mg plus ABC/3TC. Change from Baseline was defined as value at post-baseline visit minus value at Baseline.
| Proportion of red blood cells in blood | CAB LA 600 mg+RPV LA 900 mg IM-Q8W (Maintenance and Extension Period) | CAB LA 400 mg+RPV LA 600 mg IM-Q4W (Maintenance and Extension Period) | CAB 30 mg+ABC/3TC QD (Induction Period and Maintenance Period) |
|---|---|---|---|
| Week 32 | 0.01 ± 0.026 | 0.01 ± 0.027 | 0.01 ± 0.027 |
| Week 96 | 0.0114 ± 0.02880 | 0.0134 ± 0.03125 | 0.0124 ± 0.02748 |
Blood samples were collected for the analysis of hematology parameters including Hemoglobin at indicated time points. Baseline (Week -20) refers to the last available value up to and including the date of first induction period dosing with CAB 30 mg plus ABC/3TC. Change from Baseline was defined as value at post-baseline visit minus value at Baseline.
| Grams per Liter | CAB LA 600 mg+RPV LA 900 mg IM-Q8W (Maintenance and Extension Period) | CAB LA 400 mg+RPV LA 600 mg IM-Q4W (Maintenance and Extension Period) | CAB 30 mg+ABC/3TC QD (Induction Period and Maintenance Period) |
|---|---|---|---|
| Week 32 | 2.0 ± 8.56 | 0.8 ± 8.45 | 1.7 ± 8.38 |
| Week 96 | 3.9 ± 8.95 | 4.3 ± 9.92 | 4.1 ± 8.11 |
Blood samples were collected for the analysis of hematology parameters including Mean Corpuscle Volume at indicated time points. Baseline (Week -20) refers to the last available value up to and including the date of first induction period dosing with CAB 30 mg plus ABC/3TC. Change from Baseline was defined as value at post-baseline visit minus value at Baseline.
| Femtoliters | CAB LA 600 mg+RPV LA 900 mg IM-Q8W (Maintenance and Extension Period) | CAB LA 400 mg+RPV LA 600 mg IM-Q4W (Maintenance and Extension Period) | CAB 30 mg+ABC/3TC QD (Induction Period and Maintenance Period) |
|---|---|---|---|
| Week 32 | 2.5 ± 1.97 | 2.3 ± 2.54 | 7.1 ± 2.88 |
| Week 96 | 0.1 ± 2.99 | 0.3 ± 2.54 | 5.3 ± 3.14 |
Blood samples were collected for the analysis of hematology parameters including Red Blood Cell count at indicated time points. Baseline (Week -20) refers to the last available value up to and including the date of first induction period dosing with CAB 30 mg plus ABC/3TC. Change from Baseline was defined as value at post-baseline visit minus value at Baseline.
| 10^12 cells per Liter | CAB LA 600 mg+RPV LA 900 mg IM-Q8W (Maintenance and Extension Period) | CAB LA 400 mg+RPV LA 600 mg IM-Q4W (Maintenance and Extension Period) | CAB 30 mg+ABC/3TC QD (Induction Period and Maintenance Period) |
|---|---|---|---|
| Week 32 | 0.03 ± 0.286 | 0.02 ± 0.278 | -0.20 ± 0.296 |
| Week 96 | 0.12 ± 0.294 | 0.14 ± 0.310 | -0.13 ± 0.293 |
Blood samples were collected at indicated time points for pharmacokinetic (PK) analysis of CAB LA. The PK Concentration Population included all participants who received CAB LA and/or RPV LA and underwent PK sampling during the study, and provided available CAB LA and/or RPV LA plasma concentration data.
| Micrograms per milliliter | CAB LA 600 mg+RPV LA 900 mg IM-Q8W (Maintenance and Extension Period) | CAB LA 400 mg+RPV LA 600 mg IM-Q4W (Maintenance and Extension Period) |
|---|---|---|
| C0 | 1.43 ± 54 | 2.35 ± 32 |
| Cmax | 3.55 ± 56 | 3.50 ± 39 |
Blood samples were collected at indicated time points for PK analysis of RPV LA. C0 and Cmax of RPV LA (Q4W IM and Q8W IM dosing) was evaluated.
| Nanograms per milliliter | CAB LA 600 mg+RPV LA 900 mg IM-Q8W (Maintenance and Extension Period) | CAB LA 400 mg+RPV LA 600 mg IM-Q4W (Maintenance and Extension Period) |
|---|---|---|
| C0 | 49.3 ± 41 | 77.2 ± 35 |
| Cmax | 104 ± 47 | 111 ± 40 |
Blood samples were collected at indicated time points for PK analysis of CAB LA. Ctrough is the lowest concentration reached by a drug before the next dose is administered. Ctrough for CAB LA (Q8W IM dosing) which were considered for the assessment of steady state are presented.
| Micrograms per milliliter | CAB LA 600 mg+RPV LA 900 mg IM-Q8W (Maintenance and Extension Period) |
|---|---|
| Week 16, n=87 | 1.6902 ± 0.80471 |
| Week 24, n=86 | 1.6051 ± 0.78254 |
| Week 32, n=84 | 1.5330 ± 0.70822 |
Blood samples were collected at indicated time points for PK analysis of CAB LA. Ctrough is the lowest concentration reached by a drug before the next dose is administered. Ctrough for CAB LA (Q4W IM dosing) which were considered for the assessment of steady state are presented.
| Micrograms per milliliter | CAB LA 400 mg+RPV LA 600 mg IM-Q4W (Maintenance and Extension Period) |
|---|---|
| Week 16, n=78 | 2.2703 ± 0.92102 |
| Week 20, n=77 | 2.3861 ± 0.76176 |
| Week 24, n=78 | 2.6342 ± 1.29093 |
| Week 28, n=82 | 2.4365 ± 0.86420 |
| Week 32, n=85 | 2.4715 ± 0.89893 |
Blood samples were collected at indicated time points for PK analysis of RPV LA. Ctrough is the lowest concentration reached by a drug before the next dose is administered. Ctrough for RPV LA (Q8W IM dosing) which were considered for the assessment of steady state are presented.
| Nanograms per milliliter | CAB LA 600 mg+RPV LA 900 mg IM-Q8W (Maintenance and Extension Period) |
|---|---|
| Week 16, n=87 | 41.94 ± 17.575 |
| Week 24, n=85 | 47.97 ± 22.341 |
| Week 32, n=83 | 57.24 ± 22.926 |
Blood samples were collected at indicated time points for PK analysis of RPV LA. Ctrough is the lowest concentration reached by a drug before the next dose is administered. Ctrough for RPV LA (Q4W IM dosing) which were considered for the assessment of steady state are presented.
| Nanograms per milliliter | CAB LA 400 mg+RPV LA 600 mg IM-Q4W (Maintenance and Extension Period) |
|---|---|
| Week 16, n=78 | 66.92 ± 25.986 |
| Week 20, n=77 | 74.55 ± 29.156 |
| Week 24, n=78 | 76.84 ± 27.976 |
| Week 28, n=83 | 80.84 ± 31.297 |
| Week 32, n=85 | 90.34 ± 34.549 |
Logistic regression was used to examine the correlation between pharmacodynamics response (HIV-1 RNA\<50 c/mL) at Week 32 and plasma PK parameter: area under plasma concentration-time curve from time zero to the end of dosing interval (AUC \[0-tau\]) of CAB LA and RPV LA per arm using MSDF (Missing, Switch or Discontinuation = Failure) algorithm. Estimates were obtained from logistic statistical model where the dependent variable is "HIV-1 RNA\<50 c/mL" (success) and the independent variable is PK parameter (AUC \[0-tau\]). Slopes and standard error are presented. Estimated effect represents the change in log odds for a one-unit increase in the PK parameter AUC (0-tau). Standard Error (SE)=0.000 is defined as following: if for all participants was resulted same value for the specific timepoint, then SE is equal with 0.000 .
| Change in log odds | CAB LA 600 mg+RPV LA 900 mg IM-Q8W (Maintenance and Extension Period) | CAB LA 400 mg+RPV LA 600 mg IM-Q4W (Maintenance and Extension Period) | CAB 30 mg+ABC/3TC QD (Induction Period and Maintenance Period) |
|---|---|---|---|
| CAB LA | 0.00 ± 0.001 | 0.00 ± 0.002 | — |
| RPV LA | 0.00 ± 0.000 | 0.00 ± 0.000 | — |
Logistic regression was used to examine the correlation between pharmacodynamics response (HIV-1 RNA\<50 c/mL) at Week 32 and plasma PK parameter: Average C0 of CAB LA and RPV LA per arm using MSDF (Missing, Switch or Discontinuation = Failure) algorithm. Estimates were obtained from logistic statistical model where the dependent variable is "HIV-1 RNA\<50 c/mL" (success) and the independent variable is PK parameter (Average C0). Slopes and standard error are presented. Estimated effect represents the change in log odds for a one-unit increase in the PK parameter Average C0.
| Change in log odds | CAB LA 600 mg+RPV LA 900 mg IM-Q8W (Maintenance and Extension Period) | CAB LA 400 mg+RPV LA 600 mg IM-Q4W (Maintenance and Extension Period) | CAB 30 mg+ABC/3TC QD (Induction Period and Maintenance Period) |
|---|---|---|---|
| CAB LA, n=100,108, 50 | 0.64 ± 0.837 | 2.39 ± 1.903 | 0.39 ± 0.528 |
| RPV LA, n=101,104,49 | 0.00 ± 0.025 | 0.01 ± 0.039 | -0.01 ± 0.020 |
Logistic regression was used to examine the correlation between pharmacodynamics response (HIV-1 RNA\<50 c/mL) at Week 32 and plasma PK parameter: Cmax of CAB LA and RPV LA per arm using MSDF (Missing, Switch or Discontinuation = Failure) algorithm. Estimates were obtained from logistic statistical model where the dependent variable is "HIV-1 RNA\<50 c/mL" (success) and the independent variable is PK parameter (Cmax). Slopes and standard error are presented. Estimated effect represents the change in log odds for a one-unit increase in the PK parameter Cmax.
| Change in log odds | CAB LA 600 mg+RPV LA 900 mg IM-Q8W (Maintenance and Extension Period) | CAB LA 400 mg+RPV LA 600 mg IM-Q4W (Maintenance and Extension Period) | CAB 30 mg+ABC/3TC QD (Induction Period and Maintenance Period) |
|---|---|---|---|
| CAB LA, n=98, 97,0 | -0.01 ± 0.174 | 1.64 ± 1.707 | — |
| RPV LA, n=97,96,0 | 0.00 ± 0.010 | 0.01 ± 0.027 | — |
Logistic regression was used to examine the correlation between virologic failure at Week 32 and plasma PK parameter: AUC (0-tau) of CAB LA and RPV LA per arm using MSDF (Missing, Switch or Discontinuation = Failure) algorithm. Estimates were obtained from logistic statistical model where the dependent variable is "virologic failure" and the independent variable is PK parameter (AUC \[0-tau\]). Slopes and standard error are presented. Estimated effect represents the change in log odds for a one-unit increase in the PK parameter AUC (0-tau). SE=0.000 is defined as following: if for all participants was resulted same value for the specific timepoint, then SE is equal with 0.000.
| Change in log odds | CAB LA 600 mg+RPV LA 900 mg IM-Q8W (Maintenance and Extension Period) | CAB LA 400 mg+RPV LA 600 mg IM-Q4W (Maintenance and Extension Period) | CAB 30 mg+ABC/3TC QD (Induction Period and Maintenance Period) |
|---|---|---|---|
| CAB LA | -0.00 ± 0.001 | -0.00 ± 0.002 | — |
| RPV LA | 0.00 ± 0.000 | -0.00 ± 0.000 | — |
Logistic regression was used to examine the correlation between virologic failure at Week 32 and plasma PK parameter: Average C0 of CAB LA and RPV LA per arm using MSDF (Missing, Switch or Discontinuation = Failure) algorithm. Estimates were obtained from logistic statistical model where the dependent variable is "virologic failure" and the independent variable is PK parameter (Average C0). Slopes and standard error are presented. Estimated effect represents the change in log odds for a one-unit increase in the PK parameter Average C0.
| Change in log odds | CAB LA 600 mg+RPV LA 900 mg IM-Q8W (Maintenance and Extension Period) | CAB LA 400 mg+RPV LA 600 mg IM-Q4W (Maintenance and Extension Period) | CAB 30 mg+ABC/3TC QD (Induction Period and Maintenance Period) |
|---|---|---|---|
| CAB LA, n=100,108, 50 | -1.01 ± 1.014 | -2.39 ± 1.903 | -0.53 ± 0.796 |
| RPV LA, n=101,104,49 | -0.00 ± 0.027 | -0.01 ± 0.039 | -0.01 ± 0.038 |
Logistic regression was used to examine the correlation between virologic failure at Week 32 and plasma PK parameter: Cmax of CAB LA and RPV LA per arm using MSDF (Missing, Switch or Discontinuation = Failure) algorithm. Estimates were obtained from logistic statistical model where the dependent variable is "virologic failure" and the independent variable is PK parameter (Cmax). Slopes and standard error are presented. Estimated effect represents the change in log odds for a one-unit increase in the PK parameter Cmax.
| Change in log odds | CAB LA 600 mg+RPV LA 900 mg IM-Q8W (Maintenance and Extension Period) | CAB LA 400 mg+RPV LA 600 mg IM-Q4W (Maintenance and Extension Period) | CAB 30 mg+ABC/3TC QD (Induction Period and Maintenance Period) |
|---|---|---|---|
| CAB LA, n=98, 97,0 | -0.45 ± 0.509 | -1.64 ± 1.707 | — |
| RPV LA, n=97,96,0 | -0.00 ± 0.012 | -0.01 ± 0.027 | — |
Plasma samples were collected to assess treatment emergent Genotypic Resistance for participants who had confirmed virologic failure. Number of participants who had any Integrase Inhibitor (INI) mutations or major mutations of other classes (Nucleoside reverse transcriptase inhibitor \[NRTI\], Non-nucleoside reverse transcriptase inhibitor \[NNRTI\], protease inhibitor \[PI\])are presented.
| Participants | CAB LA 600 mg+RPV LA 900 mg IM-Q8W (Maintenance and Extension Period) | CAB LA 400 mg+RPV LA 600 mg IM-Q4W (Maintenance and Extension Period) | CAB 30 mg+ABC/3TC QD (Induction Period and Maintenance Period) |
|---|---|---|---|
| INI mutations | 0 | — | 0 |
| Major mutations of other classes | 0 | — | 0 |
Plasma samples were collected for drug resistance testing. Number of participants, with treatment emergent phenotypic resistance to INI, NNRTI, NRTI and/or PI were summarized. Overall susceptibility of the drug was categorized as sensitive, partially sensitive and resistant.
| Participants | CAB LA 600 mg+RPV LA 900 mg IM-Q8W (Maintenance and Extension Period) | CAB LA 400 mg+RPV LA 600 mg IM-Q4W (Maintenance and Extension Period) | CAB 30 mg+ABC/3TC QD (Induction Period and Maintenance Period) |
|---|---|---|---|
| INI, Sensitive | 1 | — | 1 |
| INI, Partially sensitive | 0 | — | 0 |
| INI, Resistant | 0 | — | 0 |
| NNRTI, Sensitive | 1 | — | 1 |
| NNRTI, Partially sensitive | 0 | — | 0 |
| NNRTI, Resistant | 0 | — | 0 |
| NRTI, Sensitive | 1 | — | 1 |
| NRTI, Partially sensitive | 0 | — | 0 |
| NRTI, Resistant | 0 | — | 0 |
| PI, Sensitive | 1 | — | 1 |
| PI, Partially sensitive | 0 | — | 0 |
| PI, Resistant | 0 | — | 0 |
Percentage of participants with HIV-1 RNA\<50 c/mL was obtained using FDA Snapshot algorithm. The algorithm treated all participants without HIV-1 RNA data at the visit of interest (due to missing data or discontinuation of investigational product prior to the visit window) as well as participants who switch their concomitant ART prior to the visit of interest, as non-responders. Data is presented for following subgroups: Baseline plasma HIV-1 RNA levels, Baseline CD4+ cell count, Race and HIV Risk factor (Homosexual contact \[HC\] and not injectable drug user).
| Percentage of participants | CAB LA 600 mg+RPV LA 900 mg IM-Q8W (Maintenance and Extension Period) | CAB LA 400 mg+RPV LA 600 mg IM-Q4W (Maintenance and Extension Period) | CAB 30 mg+ABC/3TC QD (Induction Period and Maintenance Period) |
|---|---|---|---|
| Baseline HIV-1 RNA<100000 c/mL, n=99,87,49 | 96 | 92 | 94 |
| Baseline HIV-1 RNA>=100000 c/mL, n=16,28,7 | 88 | 100 | 71 |
| Baseline HIV-1 RNA<1000 c/mL, n=0,3,1 | — | 100 | 100 |
| Baseline HIV-1 RNA 1000 to<10000c/mL, n=26,25,13 | 100 | 84 | 92 |
| Baseline HIV-1 RNA 1000 to <50000c/mL, n=50,42,25 | 49 | 39 | 24 |
| Baseline HIV-1 RNA 50000 to<100000c/mL,n=23,17,10 | 87 | 100 | 90 |
| Baseline HIV-1 RNA>=100000 to<200000c/mL,n=9,13,2 | 89 | 100 | 50 |
| Baseline plasma HIV-1 RNA >=200000 c/mL, n=7,15,5 | 86 | 100 | 80 |
| Baseline CD4+ cell count <200 cells/mm^3, n=3,2,0 | 100 | 100 | — |
| Baseline CD4+ count 200 to<350cells/mm^3,n=30,23,8 | 97 | 100 | 88 |
| Baseline CD4+ count >=350 cells/mm^3, n=82,90,48 | 94 | 92 | 92 |
| Race-White, n=93,94,39 | 95 | 94 | 95 |
| Race-Non-White, n=22,21,17 | 95 | 95 | 82 |
| HC and not injectable drug user, n=98,90,40 | 96 | 94 | 90 |
| No HC and not injectable drug user, n=17,25,16 | 88 | 92 | 94 |
Virologic failure was defined as any of the following: (1) Non-response as indicated by a less than a 1.0 log10 c/mL decrease in plasma HIV-1 RNA after 4 weeks of starting the Induction Period, which is subsequently confirmed, unless the plasma HIV-1 RNA is \< 400 c/mL; (2) Rebound as indicated by two consecutive plasma HIV-1 RNA levels \>=200 c/mL after prior suppression to \<200 c/mL; (3) Rebound as indicated by two consecutive plasma HIV-1 RNA that are \> 0.5 log10 c/mL increase in plasma HIV-1 RNA from the nadir value on study, where the lowest HIV-1 RNA value is \>=200 c/mL. Data is presented for following subgroups: Baseline plasma HIV-1 RNA levels, Baseline CD4+ cell count, Race and HIV Risk factor (Homosexual contact \[HC\] and not injectable drug user).
| Percentage of participants | CAB LA 600 mg+RPV LA 900 mg IM-Q8W (Maintenance and Extension Period) | CAB LA 400 mg+RPV LA 600 mg IM-Q4W (Maintenance and Extension Period) | CAB 30 mg+ABC/3TC QD (Induction Period and Maintenance Period) |
|---|---|---|---|
| Baseline HIV-1 RNA<100000 c/mL, n=99,87,49 | 3 | 1 | 0 |
| Baseline HIV-1 RNA>=100000 c/mL, n=16,28,7 | 13 | 0 | 29 |
| Baseline HIV-1 RNA<1000 c/mL, n=0,3,1 | — | 0 | 0 |
| Baseline HIV-1 RNA 1000 to<10000c/mL, n=26,25,13 | 0 | 4 | 0 |
| Baseline HIV-1 RNA 1000 to <50000c/mL, n=50,42,25 | 2 | 0 | 0 |
| Baseline HIV-1 RNA 50000 to<100000c/mL,n=23,17,10 | 9 | 0 | 0 |
| Baseline HIV-1 RNA>=100000 to<200000c/mL,n=9,13,2 | 11 | 0 | 50 |
| Baseline plasma HIV-1 RNA >=200000 c/mL, n=7,15,5 | 14 | 0 | 20 |
| Baseline CD4+ cell count <200 cells/mm^3, n=3,2,0 | 0 | 0 | — |
| Baseline CD4+ count 200 to<350cells/mm^3,n=30,23,8 | 0 | 0 | 13 |
| Baseline CD4+ count >=350 cells/mm^3, n=82,90,48 | 6 | 1 | 2 |
| Race-White, n=93,94,39 | 4 | 1 | 0 |
| Race-Non-White, n=22,21,17 | 5 | 0 | 12 |
| HC and not injectable drug user, n=98,90,40 | 3 | 1 | 5 |
| No HC and not injectable drug user, n=17,25,16 | 12 | 0 | 0 |
The HIVTSQ(s) was developed to evaluate treatments for HIV and participant satisfaction. It has total 14 items and each items are scored from 6 (very satisfied) to 0 (very dissatisfied). Items 1 to 12 are summed to produce the Total Treatment Satisfaction Score with a possible range of 0 to 72. Higher scores represent greater treatment satisfaction as compared to the past few weeks.
| Scores on a scale | CAB LA 600 mg+RPV LA 900 mg IM-Q8W (Maintenance and Extension Period) | CAB LA 400 mg+RPV LA 600 mg IM-Q4W (Maintenance and Extension Period) | CAB 30 mg+ABC/3TC QD (Induction Period and Maintenance Period) |
|---|---|---|---|
| Week 32 | 68.4 ± 4.48 | 66.6 ± 6.47 | 65.1 ± 5.83 |
| Week 96 | 68.4 ± 4.34 | 67.0 ± 5.20 | 63.5 ± 9.75 |
The HIVTSQ(c) was developed to evaluate treatments for HIV and participant satisfaction. It has total 14 items and each items are scored from +3 ('much more satisfied', 'much more convenient', 'much more flexible', etc.) to -3 ('much less satisfied', 'much less convenient', 'much less flexible', etc.). Items 1 to 12 (excluding Items 7b and 9b) are summed to produce a Total Treatment Satisfaction Score (change) with a possible range of -33 to +33. The higher the score, the greater the improvement in satisfaction with treatment; the lower the score, the greater the deterioration in satisfaction with treatment.
| Scores on a scale | CAB LA 600 mg+RPV LA 900 mg IM-Q8W (Maintenance and Extension Period) | CAB LA 400 mg+RPV LA 600 mg IM-Q4W (Maintenance and Extension Period) | CAB 30 mg+ABC/3TC QD (Induction Period and Maintenance Period) |
|---|---|---|---|
| HIV Treatment Satisfaction Questionnaire - Change Version (HIVTSQ[c]) Total Score at Week 32 (Maintenance Period) | 30.9 ± 7.56 | 28.9 ± 8.53 | 20.5 ± 14.09 |
The HIVMQ was developed to assess participant reported medication adherence. It has 6 items (a, b, c, d, e, f). Item E (How often do you find it inconvenient or difficult to take/receive medication as recommended?) and Item F (How much pain/discomfort have experienced with this medication?). Each of these 2 items are scored from 0 (none of the time) to 6 (all of the time). The higher the score, the greater the adherence to medication. Number of participants with HIVMQ Item E and F Scores at Week 32 by their score categories (0: none of the time to 6: all of the time) are presented.
| Participants | CAB LA 600 mg+RPV LA 900 mg IM-Q8W (Maintenance and Extension Period) | CAB LA 400 mg+RPV LA 600 mg IM-Q4W (Maintenance and Extension Period) | CAB 30 mg+ABC/3TC QD (Induction Period and Maintenance Period) |
|---|---|---|---|
| Item E, score 0 | 80 | 73 | 16 |
| Item E, score 1 | 12 | 14 | 13 |
| Item E, score 2 | 3 | 2 | 2 |
| Item E, score 3 | 2 | 6 | 3 |
| Item E, score 4 | 0 | 1 | 1 |
| Item E, score 5 | 2 | 4 | 12 |
| Item E, score 6 | 10 | 6 | 3 |
| Item F, Score 0 | 40 | 33 | 29 |
| Item F, Score 1 | 35 | 43 | 12 |
| Item F, Score 2 | 17 | 16 | 2 |
| Item F, Score 3 | 6 | 5 | 2 |
| Item F, Score 4 | 7 | 3 | 3 |
| Item F, Score 5 | 4 | 4 | 0 |
| Item F, Score 6 | 0 | 2 | 2 |
The HIVMQ was developed to assess participant reported medication adherence. It has 6 items (a, b, c, d, e, f). Item E (How often do you find it inconvenient or difficult to take/receive medication as recommended?) and Item F (How much pain/discomfort have experienced with this medication?). Each of these 2 items are scored from 0 (none of the time) to 6 (all of the time). The higher the score, the greater the adherence to medication. Number of participants with HIVMQ Item E and F Scores at Week 96 by their score categories (0: none of the time to 6: all of the time) are presented.
| Participants | CAB 30 mg+ABC/3TC QD (Induction Period and Maintenance Period) |
|---|---|
| Item E, score 0 | 18 |
| Item E, score 1 | 10 |
| Item E, score 2 | 3 |
| Item E, score 3 | 2 |
| Item E, score 4 | 1 |
| Item E, score 5 | 9 |
| Item E, score 6 | 3 |
| Item F, Score 0 | 3 |
| Item F, Score 1 | 8 |
| Item F, Score 2 | 4 |
| Item F, Score 3 | 1 |
| Item F, Score 4 | 0 |
| Item F, Score 5 | 1 |
| Item F, Score 6 | 1 |
Collected over All-cause mortality, SAEs and non-SAEs were collected from start of the study treatment up to end of Extension and LTFU Periods (up to approximately 468 weeks).. Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| CAB 30 mg+ABC/3TC QD (Induction Period) | 1/309 (0.3%) | 8/309 (2.6%) | 145/309 (46.9%) |
| CAB LA 600 mg+RPV LA 900 mg IM-Q8W (Maintenance and Extension Period) | 0/115 (0%) | 31/115 (27%) | 115/115 (100%) |
| CAB LA 400 mg+RPV LA 600 mg IM-Q4W (Maintenance and Extension Period) | 3/115 (2.6%) | 31/115 (27%) | 115/115 (100%) |
| CAB 30 mg+ABC/3TC QD | 0/56 (0%) | 9/56 (16.1%) | 52/56 (92.9%) |
| Optimized CAB LA 600 mg+RPV LA 900 mg IM-Q8W (Extension Period) | 0/34 (0%) | 9/34 (26.5%) | 34/34 (100%) |
| Optimized CAB LA 400 mg+RPV LA 600 mg IM-Q4W (Extension Period) | 0/10 (0%) | 1/10 (10%) | 10/10 (100%) |
| Long-Term Follow-Up Group | 0/43 (0%) | 7/43 (16.3%) | 7/43 (16.3%) |
| Event | CAB 30 mg+ABC/3TC QD (Induction Period) | CAB LA 600 mg+RPV LA 900 mg IM-Q8W (Maintenance and Extension Period) | CAB LA 400 mg+RPV LA 600 mg IM-Q4W (Maintenance and Extension Period) | CAB 30 mg+ABC/3TC QD | Optimized CAB LA 600 mg+RPV LA 900 mg IM-Q8W (Extension Period) | Optimized CAB LA 400 mg+RPV LA 600 mg IM-Q4W (Extension Period) | Long-Term Follow-Up Group |
|---|---|---|---|---|---|---|---|
| VIth nerve paralysisNervous system disorders | 0/309 | 0/115 | 0/115 | 0/56 | 0/34 | 1/10 | 0/43 |
| PneumoniaInfections and infestations | 0/309 | 0/115 | 0/115 | 0/56 | 2/34 | 0/10 | 0/43 |
| Suicide attemptPsychiatric disorders | 0/309 | 2/115 | 1/115 | 0/56 | 0/34 | 0/10 | 2/43 |
| Road traffic accidentInjury, poisoning and procedural complications | 1/309 | 0/115 | 0/115 | 0/56 | 1/34 | 0/10 | 0/43 |
| Abdominal painGastrointestinal disorders | 0/309 | 0/115 | 1/115 | 0/56 | 1/34 | 0/10 | 0/43 |
| COVID-19 pneumoniaInfections and infestations | 0/309 | 0/115 | 0/115 | 0/56 | 1/34 | 0/10 | 0/43 |
| Gastroenteritis viralInfections and infestations | 0/309 | 0/115 | 0/115 | 0/56 | 1/34 | 0/10 | 0/43 |
| Meningitis asepticInfections and infestations | 0/309 | 0/115 | 0/115 | 0/56 | 1/34 | 0/10 | 0/43 |
| Abdominal pain upperGastrointestinal disorders | 0/309 | 0/115 | 0/115 | 0/56 | 1/34 | 0/10 | 0/43 |
| Tendon ruptureInjury, poisoning and procedural complications | 0/309 | 0/115 | 0/115 | 0/56 | 1/34 | 0/10 | 0/43 |
| Event | CAB 30 mg+ABC/3TC QD (Induction Period) | CAB LA 600 mg+RPV LA 900 mg IM-Q8W (Maintenance and Extension Period) | CAB LA 400 mg+RPV LA 600 mg IM-Q4W (Maintenance and Extension Period) | CAB 30 mg+ABC/3TC QD | Optimized CAB LA 600 mg+RPV LA 900 mg IM-Q8W (Extension Period) | Optimized CAB LA 400 mg+RPV LA 600 mg IM-Q4W (Extension Period) | Long-Term Follow-Up Group |
|---|---|---|---|---|---|---|---|
| Injection site painGeneral disorders | 0/309 | 111/115 | 114/115 | 0/56 | 31/34 | 8/10 | 4/43 |
| Injection site noduleGeneral disorders | 0/309 | 46/115 | 57/115 | 0/56 | 12/34 | 5/10 | 0/43 |
| NasopharyngitisInfections and infestations | 27/309 | 54/115 | 54/115 | 22/56 | 8/34 | 5/10 | 0/43 |
| Injection site swellingGeneral disorders | 0/309 | 41/115 | 43/115 | 0/56 | 6/34 | 3/10 | 0/43 |
| Injection site pruritusGeneral disorders | 0/309 | 40/115 | 40/115 | 0/56 | 4/34 | 2/10 | 0/43 |
| DiarrhoeaGastrointestinal disorders | 34/309 | 39/115 | 35/115 | 11/56 | 4/34 | 3/10 | 0/43 |
| SyphilisInfections and infestations | 0/309 | 36/115 | 28/115 | 6/56 | 4/34 | 3/10 | 0/43 |
| InfluenzaInfections and infestations | 0/309 | 21/115 | 32/115 | 0/56 | 7/34 | 3/10 | 0/43 |
| Back painMusculoskeletal and connective tissue disorders | 0/309 | 27/115 | 30/115 | 10/56 | 8/34 | 3/10 | 0/43 |
| ArthralgiaMusculoskeletal and connective tissue disorders | 0/309 | 27/115 | 21/115 | 4/56 | 6/34 | 3/10 | 0/43 |
309 participants are valid only for the Induction Phase of the study (Weeks -20 to Day 1). Participants (n=286) were randomized at Day 1 of the Maintenance Phase.
| Age, Continuous(Years) | CAB 30 mg+ABC/3TC QD |
|---|---|
| Mean | 36.6 ± 10.39 |
| Sex: Female, Male(Participants) | CAB 30 mg+ABC/3TC QD |
|---|---|
| Female | 27 |
| Male | 282 |
| Race/Ethnicity, Customized(Participants) | CAB 30 mg+ABC/3TC QD |
|---|---|
| Race — African American/African Heritage | 46 |
| Race — American Indian or Alaskan Native | 10 |
| Race — Asian - Central/South Asian Heritage | 1 |
| Race — Asian - Japanese Heritage | 1 |
| Race — Asian - South East Asian Heritage | 2 |
| Race — Native Hawaiian or Other Pacific Islander | 1 |
| Race — White - Arabic/North African Heritage | 6 |
| Race — White - White/Caucasian/European Heritage | 240 |
| Race — Mixed Race | 2 |
PDFs hosted by the registry, ClinicalTrials.gov.
Plan to share: Yes — IPD for this study will be made available via the Clinical Study Data Request site.
Supporting information: Study protocol, Statistical analysis plan, Informed consent form, Clinical study report
Time frame: IPD will be made available within 6 months of publishing the results of the primary endpoints, key secondary endpoints and safety data of the study.
Access criteria: Access is provided after a research proposal is submitted and has received approval from the Independent Review Panel and after a Data Sharing Agreement is in place. Access is provided for an initial period of 12 months but an extension can be granted, when justified, for up to another 12 months.
Data sharing details ↗ · clinicalstudydatarequest.com
Ran from Apr 2014 to primary completion in Aug 2015, 15 months.
Results were first posted in Aug 2020, 5 years after primary completion. A results delay was requested in Dec 2015.
Of 34 industry-sponsored phase 2 interventional studies under HIV Infections, half reached primary completion within 19 months of starting (the median), counting those still running; a quarter within 12 and three quarters within 31. This study's 15 months is below that.
Counting every sponsor, half of 99 studies reached it within 31 months; a quarter within 17 and three quarters within 58.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Jun 2024. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Cabotegravir